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Abstract
Quantifying Passive Drug Transport across Lipid Membranes
JEHANGIR CAMA
Biological and Soft Systems
Department of Physics, Cavendish Laboratory
Antibiotic resistance has emerged as one of theWorld’s leading public health challenges.
The inexorable emergence of drug resistant pathogens, combined with a steep decline
in antibacterial drug discovery, has led to a major crisis. One of the most common drug
resistance mechanisms involves bacteria adapting to reduce intracellular drug accumu-
lation. To understand these resistance mechanisms, one needs quantitative information
about the membrane permeability of drugs. In this Thesis, we develop a novel optoflu-
idic permeability assay that allows us to quantify the permeability coefficient of drugs
crossing lipid membranes. Lipid vesicles are used as model systems and drug molecules
are tracked directly using their autofluorescence in the ultraviolet. The permeability
coefficient of the drug is inferred by studying the increase in drug autofluorescence
intensity within vesicles as they traverse a microfluidic network while exposed to the
drug for well defined times. This provides a novel platform from which we can develop
membrane models for understanding drug permeability.
We incorporate the Escherichia coli outer membrane protein OmpF in vesicles and
quantify its role in the transport of fluoroquinolone antibiotics. We provide direct
visualisation of OmpF mediated fluoroquinolone transport. We study the pH depen-
dence of antibiotic transport both through pure phospholipid membranes and through
OmpF, and present a physical mechanism to explain the pH dependence of E. coli
v
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fluoroquinolone susceptibility. We also show the importance of lipid composition on
drug permeability − changing the lipid composition of the membrane is shown to
change antibiotic permeability by over an order of magnitude. Finally, we report on
the discovery of a novel signalling mechanism in E. coli that relies on the transport of
small drug-like molecules, and discuss the role it plays in stress response in the microbial
community.
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Introduction
“There are more things in heaven and earth, Horatio, than are dreamt of in
your philosophy.”
Hamlet (The Tragedy of Hamlet, Prince of Denmark)
“Chance favours the prepared mind.” So pronounced Louis Pasteur, doyen of 19th
century microbiology and inventor of sterilization protocols still in use today. What
irony then that, just two years after Pasteur’s death, at the institute named in his
honour, a remarkable discovery by one Ernest Duchesne went unheeded. Duchesne, in
the course of his graduate studies, had observed that fungi from the genus Penicillium
were capable of destroying pathogenic bacteria both in laboratory cultures and when
injected into guinea pigs [1]. His proposal of exploiting this bacteriostatic property of
the mould for therapeutic purposes fell on deaf ears, and one of medicine’s greatest ever
discoveries fell, temporarily, by the wayside.
Exactly 33 years to the day after Pasteur’s death, on the 28th of September 1928, the
Scottish biologist Alexander Fleming noticed that one of his culture plates of Staphy-
loccocus bacteria was contaminated with mould. Remarkably, the bacterial colonies
around the mould were transparent, suggesting that the bacteria were undergoing lysis
[2]. On investigating, he found that the mould belonged to the genus Penicillium;
he had in essence rediscovered Duchesne’s observations. However, unlike Duchesne
and his superiors at the Pasteur Institute, Fleming recognized the significance of his
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discovery and isolated the antibacterial chemical, which he named penicillin, that was
produced by the mould. As he remarked in his Nobel lecture [3]:
“....penicillin started as a chance observation. My only merit is that I did
not neglect the observation and that I pursued the subject as a bacteriolo-
gist.”
Chance did indeed favour the prepared mind, then.
The rest, as they say, is history. Penicillin was amongst the first of many antibiotics
to be discovered and synthesized, and completely changed the face of the medical and
pharmaceutical industries. Surgical procedures became much safer, typhoid, plague,
tuberculosis and other dreaded diseases no longer carried death sentences, and average
life expectancy rates climbed steadily higher. According to Ms. Zsuzsanna Jakab,
Regional Director for Europe, World Health Organization, “The use of antibiotics
− and vaccines − has lengthened our life-spans by 20 years on average”. Antibiotics
form the bedrock of all modern medicine. The discovery of penicillin can rightfully
claim to be amongst the most influential in the history of humanity.
However, bacteria have not survived on Earth for billions of years without an extraor-
dinary amount of resilience. Their rapid growth rate allows for the prompt selection
of mutant organisms capable of resisting external stress. Fleming acknowledged this
danger in his Nobel speech, saying [3]:
“It is not difficult to make microbes resistant to penicillin in the labora-
tory by exposing them to concentrations not sufficient to kill them, and
the same thing has occasionally happened in the body......there is danger
that the ignorant man may easily underdose himself and by exposing his
microbes to non-lethal quantities of the drug, make them resistant.”
Inevitably, resistance began appearing almost immediately after the introduction of
antimicrobials in the clinic. Sulfonamides, introduced in 1937, saw resistance develop
just a couple of years after their introduction − the same sulfonamide resistance mech-
anisms operate today [4]. The cause of resistance was not limited to antibiotic under-
exposure. Before penicillin was even introduced therapeutically, members of the peni-
cillin discovery team found a bacterial enzyme that was capable of destroying the drug
3[5]. This is due to the fact that a number of antibiotic resistance genes are found
naturally in microbial populations [4, 6]. The use of penicillin led to the spread of genes
encoding β-lactamases, the enzymes capable of cleaving penicillin, and synthetic studies
had to be undertaken to chemically modify penicillin to protect against degradation by
these enzymes [4].
By the 1950s, resistance to multiple antimicrobials was being reported in Japan −
Shigella dysenteriae strains resistant to upto four different antibiotics were isolated [7].
Even more worryingly, it was found that the multiple antibiotic resistance characteris-
tics of S. dysenteriae could be transferred to other Enterobacteriaceae by simply mixing
liquid cultures of sensitive and resistant bacteria and plating them out on solid media
[7]. It turned out that resistance genes were being transferred via plasmid exchange
between bacteria, and that this exchange was carried out by cell-to-cell contact [7, 8].
Multidrug resistance, thus, is an example of infective heredity in bacteria [8, 9].
However, a common trait emerged from these initial studies − investigations into the
biochemical mechanisms of resistance revealed that multidrug resistance was caused
by a decrease in the cell permeability of drugs [8]. Understanding drug permeability
therefore became a critical issue in the study of antibiotic resistance. It is to the study
of drug transport that the majority of this Thesis is devoted.
In hindsight, it should have come as no surprise that reduced cell permeability was
the route of choice for the development of multidrug resistance. The cell membrane
provides all cells with their first line of defence against external stress. Most antibiotic
targets are found in the cytoplasm [10], and hence preventing drugs from reaching
their targets seems one of the obvious things to do, from the perspective of the cell.
The reduced influx (or increased eﬄux) of drug molecules confers protection against
all drugs with intracellular targets; the bacterial equivalent of killing many birds with
one stone, as it were.
In order to elucidate the mechanisms by which bacteria can adapt their cell mem-
branes to make them less permeable, we need to understand how drugs interact with
the various components of the membrane. Cell membranes typically consist of lipid
bilayers which contain a number of proteins embedded in them. The number of
membranes can vary−Gram-positive bacteria have a single membrane, whereas Gram-
negative bacteria have a double membrane cell wall. The lipid bilayers present in these
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membranes contain non-polar, hydrophobic cores, and hence pose a significant barrier
for polar molecules and ions attempting entry into the cell. The cellular entry of
such moieties is controlled by a variety of membrane protein channels, that provide
a pathway for these molecules and ions across the lipid barrier.
To understand drug permeability, then, one has to understand how drugs translocate
across both the lipid barrier as well as across these membrane protein channels. This
is of fundamental importance in drug design and development. However, such mea-
surements pose significant challenges − attempting measurements on live bacteria is
difficult due to their small size. Furthermore, traditional microbiology involves bulk
experiments, where populations of cells are sampled. Bulk experiments are not very
conducive to the quantitative study of membrane transport processes. Additionally,
with whole cell experiments, it is very challenging to quantify transport through differ-
ent permeation pathways since there is little control over the system. New techniques
are thus required to tackle the membrane transport problem quantitatively, with an
emphasis on control over the experimental system under investigation.
From a physicist’s perspective, the obvious way to tackle such a complicated problem
was by removing as many complications as possible. Biologists tend to take the oppo-
site approach. To understand transport, they would knock out, one by one, various
proteins implicated in transport and measure the response. However, one can never be
sure of the side effects of removing particular proteins on the overall physiology of the
cell, and we therefore settled on a bottom-up approach to the problem. If the major
constituent of cell membranes is the lipid bilayer, why not first understand the role that
the lipid bilayer alone has to play in drug transport? Once the baseline level of passive,
diffusive transport across the lipid bilayer is quantified, one can start incorporating
protein channels into the lipid membrane and quantify the effect of each individual
type of membrane protein on transport in a completely unambiguous manner. Of
course, we cannot replicate the conditions existing in a living cell, but for studying
passive diffusion, which is one of the most important modes of drug transport [11, 12],
this approach yields quantitative and comprehensive results.
In this Thesis, we develop a new microfluidic approach to quantify drug permeability
across pure lipid membranes. We use Giant Unilamellar Vesicles (GUVs) as our model
lipid systems, and study drug accumulation within the vesicles as they traverse a mi-
5crofluidic channel network while exposed to the drug. We exploit the ultraviolet (UV)
autofluorescence properties of various antibiotics to track their molecules in a label-free
manner, thus directly measuring the membrane permeation of the drug. After measur-
ing the baseline permeability of the lipid membrane, we incorporate the Escherichia
coli outer membrane protein pore OmpF in our vesicle membranes and study the
effect of these pores on drug uptake. Our approach enabled the direct visualisation of
OmpF-mediated antibiotic uptake in a manner not previously possible. Combining our
measurements on lipid and OmpF-mediated transport allowed us to present a physical
mechanism explaining the pH dependence of fluoroquinolone antibiotic susceptibility
in E. coli.
In addition to our studies on drug permeability, we report on the discovery of a novel
signalling mechanism in E. coli. This signalling mechanism relies on the ability of
indole, a small drug-like molecule, to diffuse passively across bacterial membranes −
membrane transport is thus fundamental to bacterial signalling as well. Understanding
bacterial communication and signalling in response to stress is vital in the battle against
antibiotic resistance, and we propose that the indole pulse signalling mechanism that
we discovered is part of a widespread stress response in E. coli. This further extends the
scope of our permeability technique, since we can also examine the effect of indole and
other signalling molecules on drug permeability.
The Thesis is structured thus:
Chapter 2 introduces our new microfluidic technique. We discuss the need for tech-
nological development in the field, explain our model systems and optical setup, and
lay the experimental and theoretical foundations for the optofluidic permeability assay
that we developed.
Chapter 3 describes the results that we obtained on studying transport across pure
phospholipid membranes. We validate theoretical predictions for the pH dependence of
the transport of norfloxacin, a fluoroquinolone antibiotic, across lipid membranes and
measure its permeability coefficient. We show the importance of studying transport
in the lipid system of interest − changing the lipid molecule leads to an order of
magnitude change in the norfloxacin permeability. We further report measurements
on the permeability of tetracycline, a different class of antibiotic. We conclude the
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chapter with a measurement of the permeability of Quantum Dots, in order to show
the versatility of our technique in studying a variety of systems.
Chapter 4 deals with the results of transport through the OmpF pore. Reconstituting
OmpF in the vesicle membranes makes themmuchmore permeable to norfloxacin, and
we quantify the flux through these pores. Our technique allows us to quantify, indepen-
dently, transport through the pores and transport through the lipids, a measurement
that was not feasible in the past.
Chapter 5 reports on the measurements that we undertook in order to elucidate the
indole pulse signalling mechanism. This work was carried out in collaboration with the
group of Dr. David Summers (Dept. of Genetics, Cambridge), and we shall explain the
assay that we used to measure cell associated indole concentrations. This measurement
was required in order to quantify the concentrations of indole achieved within cells
during the pulse signal.
Chapter 6 details the outlook for our permeability assay. We discuss ways to improve
on the technique and describe other uses that the assay is being put to, such as the study
of ion transport through nanopores. We also discuss future developments that would
enable us to modify our assay for single cell analysis, providing a tool to distinguish
resistant cells from normal cells in a clinical setting. A discussion on future directions
for indole signalling research is also provided.
Chapter 7 contains some brief concluding remarks.
Antibiotic resistance is too important a problem for the wider non-biology community
to ignore. It is a challenge that must involve the collective scientific might of humanity,
encompassing biologists, physicists, mathematicians, chemists, programmers, engineers
and others. This work is a small example of how research in a physics laboratory can be
applied to a pressing medical problem, and one hopes that the reader will be left with a
better understanding of drug-membrane interactions by the conclusion of this Thesis.
We shall now commence our discussion on the experimental and theoretical design of
the new permeability assay.
Chapter 2
Experimental Design
“Try not! Do, or do not, there is no try.”
Yoda (The Empire Strikes Back)
2.1 Introduction1
We begin our discussion of membrane transport by outlining the basic technical prob-
lems that experimentalists encounter when studying drug permeation across biological
membranes. We shall introduce the concept of autofluorescence and describe how
we exploit this property of drug molecules to track them in a label-free manner, thus
circumventing a whole host of problems in the field. Our interests lie mainly in the
study of antibiotic transport, and thus our emphasis and techniques will be tailored to
the study of these drugs. However, the techniques developed can easily be adapted to
study the membrane permeability of other molecules of interest.
The rest of this chapter will be dedicated to describing a new microfluidic assay to
measure the permeability of drugs across lipid membranes.
1We published most of the work presented in this chapter and part of the following chapter in
reference [13].
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2.1.1 The need for technological development
Consider the following scenario: you are working in the pharmaceutical industry,
on the development of a promising new drug. In vitro screens have shown that the
molecule binds well to its intended target within the cell. But tests on actual living cells
are failing to show desired results. What could possibly be wrong?
The obvious next step would be to check whether the drug is actually accumulating
inside the cell. One would imagine that such an important process in drug development
had been optimised years ago, taking into account the tremendous biochemical variety
of cellular membranes and having specific assays to test drugs against particular cell
types.
The reality couldn’t be more different.
The cell permeation capabilities of drug molecules are typically estimated in the phar-
maceutical industry by the measurement of their partition coefficients (K ) in com-
pletely artificial aqueous:organic phase systems [14]. The solvents generally used for
the purpose are water and octanol. The premise is that octanol, being hydrophobic, is a
good approximation for the non-polar, hydrophobic core of lipid bilayers that form the
main barrier preventing drug molecules from entering the cell. The partition coefficient
measurement involves mixing water and octanol with the drug under investigation, and
measuring how the drug preferentially partitions into the two solvents. The result is
generally reported in terms of a log scale:
logKoct/water = log
(
[solute]octanol
[solute]water
)
(2.1)
Actual drug permeability and flux across lipid membranes is not measured directly; it
is inferred from a knowledge of the partition coefficient and the diffusion coefficient
of the drug in a generic non-polar phase [15]. This technique, although suitable for a
qualitative understanding of drug lipophilicity, completely disregards the tremendous
variety in membrane compositions found in cells. The lipid composition of the mem-
brane can vary significantly, not just between species, but even in the same cell under
different environmental conditions [16, 17]. An ability to directly measure drug per-
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meability across lipid membranes would therefore represent a significant improvement
over this method.
Another industry standard for estimating drug absorption in the human intestine in-
volves the use of a culture of Caco-2 cells. The Caco-2 cell line consists of heterogeneous
human epithelial colorectal adenocarcinoma cells, and hence a confluent layer of these
cells is considered to be a good in vitro model for testing the absorption of drugs
in the human gut. However, the inherent heterogeneity in the cell line combined
with different culture conditions in labs across the world has led to a divergence in
the properties of some of the cell lines, making results from different laboratories
difficult to compare [18]. Further, this technique only provides information about drug
absorption into the human bloodstream; the membrane barrier of the target cell is not
considered here. This technique also cannot differentiate between active and passive
transport and is therefore not suitable for studying the finer details of drug permeation
[19].
Figure 2.1 – Cross section of the PAMPA ExplorerTM sandwich plate sold by BioTek
Instruments, Inc. (www.biotek.com). The flux of molecules across a filter supporting
a lipid bilayer is measured using UV spectroscopy.
PAMPA (parallel artificial membrane permeability assay) is yet another commonly
used technique that measures the flux of a drug crossing an artificial membrane [20].
It involves using microtiter plates where artificial lipid bilayers are formed on a hy-
drophobic filter material. The solute of interest is added to one side of the bilayer, and
its transport across is measured using UV spectroscopy (Figure 2.1). The flux values are
calculated by comparing the UV absorption of the sample against a reference well in the
plate devoid of a lipid bilayer [20]. It is believed, however, that residual solvents in the
membrane affect permeation kinetics studied using this technique [19]. Furthermore,
the use of PAMPA in measuring absorption due to transporter-mediated processes is not
advisable [21]. An investigation into the technique by industry scientists concluded:
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“Upon examination of the quality of data and quantity of time, the PAMPA assay may
be a very limited asset to a drug discovery effort” [22].
From a drug development point of view, there is thus an obvious incentive for inventing
new techniques capable of studying drug transport across lipid membranes in a direct,
quantitative manner, and where the model lipid system can be tuned to imitate the lipid
composition of target cells as closely as possible.
However, another major motivation for the development of new drug permeation
assays is for the better understanding of antibiotic resistance in bacteria. A majority
of antibacterials work by targeting processes occurring in the bacterial cytoplasm;
thus, one of the major forms of antibiotic resistance involves bacteria adapting to
decrease intracellular drug accumulation by mutations in transport pathways, lipid
compositions or by switching on eﬄux pumps [23].
Studying drug accumulation in bacteria is a complicated process, and various different
approaches have been tried. Experiments involving tracking radiolabelled quinolone
antibacterial agents [24], bioassays [25] and fluorescence based measurements [26, 27]
have been used to study the uptake of antibiotics in bacterial cells in a range of en-
vironmental conditions. However, the use of different experimental conditions and
antibiotics has complicated the comparison of results from these various techniques
[28]; no one method has been standardized and used across species and drugs. A
better understanding of drug-lipid interactions and a more reliable, quantitative assay
for determining drug permeability is therefore required.
2.1.2 UV autofluorescence and Label-Free tracking
A major obstacle in studying the transport of small molecules in biological systems is
the fact that they generally need to be tagged to track their movement and accumula-
tion. This can be done via radiolabelling or by attaching a fluorophore to the molecule
being studied. Radiolabelling is generally a tedious process, which can also change the
biological activity of the molecule being studied [27]. Attaching a fluorescent tag to a
drug molecule is likely to change its transport properties and kinetics, since the size of
the fluorophore is generally either comparable or (in many cases) much larger than the
molecule being tagged. Furthermore, with fluorescent tags one has to always worry
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about chemical properties such as the binding constants of the molecule and its tag, an
understanding of which is critical for the correct interpretation of concentrations from
intensity measurements.
However, a large proportion of biomolecules and drugs have aromatic rings that absorb
strongly in the ultraviolet region of the spectrum. When the molecule relaxes to its
ground state, it emits light (fluorescence) at a wavelength higher than that absorbed.
This fluorescence is intrinsic to the molecule, and is therefore termed ‘autofluores-
cence’.
While UV absorption has been used in the past for studying drug transport [26], the
use of UV autofluorescence microscopy is rather more recent [27]. In fact, autofluores-
cence is normally considered a problem in biological applications, since it can interfere
with conventional fluorescence microscopy techniques. Removing autofluorescence is
a considerable technical challenge [29]. The use of UV imaging in cells always requires
a delicate balance with regards to the illumination intensity − too little and the poor
signal to noise ratio (SNR) of the image will render it useless, too much and one risks
damaging the cell and changing its biological activity.
However, if one uses model systems rather than cells, a drug’s UV autofluorescence
offers a very direct, easy to use platform for tracking drug accumulation and transport.
Drug concentrations can be directly correlated with the autofluorescence intensity
enabling the direct visualisation of drug transport across lipid barriers. Fortunately
for us, a number of antibiotics are indeed autofluorescent in the UV, and we develop
our assay using the fluoroquinolone antibiotic, norfloxacin, described below.
2.1.3 Norfloxacin as a model antibiotic
Norfloxacin (Figure 2.2) is part of the fluoroquinolone family of antibiotics. These
molecules target the complexes formed between bacterial DNA and topoisomerases.
Topoisomerases are the enzymes that control the supercoiling of DNA within the cell.
The disruption of such complexes inhibits DNA synthesis thus causing cell death [30–
32]. In particular, quinolones target the enzymes DNA gyrase and topoisomerase IV;
it is generally accepted that the Gram-negative activity of quinolones is linked to gyrase
inhibition and the Gram-positive activity to topoisomerase IV inhibition [32].
12 Chapter 2 Experimental Design
O
OH
F
N
HN
O
N
Figure 2.2 – Norfloxacin molecule. Source: www.wikipedia.org
Since the targets are intracellular, quinolone accumulation within the cell becomes
critical to their efficacy. Understanding the membrane permeability of quinolones is
thus crucial. Norfloxacin (and other fluoroquinolones) are ideal candidates for develop-
ing permeability assays, since their autofluorescence allows us to develop microscopy
techniques that can directly track the molecules as they cross membrane barriers.
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Figure 2.3 – UV absorbance characteristics of a 12.5 μM solution of norfloxacin
prepared in 200 mM sucrose. Measured using a Cary 300 Bio UV VIS
spectrophotometer.
The UV absorbance characteristics of norfloxacin are presented in Figure 2.3. There
is a well defined peak in the deep UV, with maximum absorbance at 276 nm, and a
broader secondary peak at around 325 nm. In order to best exploit an autofluorescence
assay, then, one would like to be able to work in the deep UV, at excitation wavelengths
around 280 nm.
2.1 Introduction 13
However, setting up the optics required for deep UV epifluorescence proves to be sur-
prisingly difficult. Standard borosilicate glass is opaque to wavelengths below 300 nm,
and absorbs strongly in the 300-350 nm range as well. Therefore, for all deep UV
fluorescence microscopes, the optical components require special UV-grade fused silica
(or quartz) glass. Most importantly, the objective through which the excitation beam
passes must transmit in the deep UV, and thus should be made of quartz. High quality
quartz objectives, it turns out, are notoriously difficult to obtain and most of the high
numerical aperture UV objectives in use today have sufficient transmission only down
to about 330 nm.
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Figure 2.4 –Autofluorescence intensity profile (λex = 340 nm) of a 12.5 μM solution of
norfloxacin prepared in 200 mM sucrose. Measured using a Cary Eclipse Fluorimeter.
We therefore decided to use the secondary excitation peak of norfloxacin for our fluo-
rescence assay, with an excitation wavelength of 340 nm (Figure 2.4). The emitted light
peaks at a wavelength around 440 nm, well into the visible region of the spectrum,
which is easy to detect with standard cameras and detection systems. Norfloxacin was
thus a suitable candidate antibiotic for setting up our permeability assay. As we shall
see in the following chapters, the technique can be extended to other drug molecules
and nanoparticles as well. We must now turn our attention to choosing a suitable lipid
system for the assay.
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2.1.4 Giant Unilamellar Vesicles as Model Lipid Systems
Passive diffusion across the membrane is thought to account for the absorption of 80-
95% of commercial drugs [11, 12]. Lipid model systems for studying passive diffusion
thus play an important role in the study of drug uptake.
The first model lipid systems involving reconstituted cell membranes were created
by Mueller and his coworkers in 1962 [33]. This led to the development of lipid
electrophysiology, traditionally involving the preparation of “black” lipid membranes
(so called because under reflected light, destructive interference between light reflected
off the two layers of the membrane bilayer makes the structure appear dark) across
apertures in a teflon film separating two reservoirs [34]. However, these techniques are
not easily integrated with microscopy, and generally involve the application of electric
fields; diffusion is therefore not necessarily passive.
An alternative approach was the use of lipid vesicles as model systems. A lipid vesicle
(also known as a ‘liposome’) consists of a lipid membrane that encapsulates a fluid.
They form due to the amphipathic character of phospholipid molecules. Phospholipid
molecules typically contain a polar headgroup followed by a non-polar hydrocarbon
chain. In aqueous solutions, these molecules tend to form bilayers which maximise
the interaction of the polar headgroups with water while minimising the interaction of
the hydrophobic hydrocarbon chain with water. Energetically, the formation of closed,
spherical vesicles is favoured, and thus simply shaking a lipid film in an aqueous solution
gives rise to vesicles. However, such a process offers very little control over vesicle
size, and also tends to favour the production of multilamellar vesicles with multiple
phospholipid layers.
A popular early method for vesicle production was by extrusion; a lipid suspension
in an aqueous medium is “extruded” (pushed) through pores with diameters ranging
from tens to hundreds of nm. This provides a monodisperse population of unilamellar
vesicles, with a relatively narrow size distribution [35]. However, this technique fails to
produce vesicles with diameters exceeding 1 μm and thus is not easily compatible with
microscopy studies. We require giant unilamellar vesicles (GUVs), whose diameters
can be in the tens of microns; these are traditionally created by a process known as
electroformation [36]. This involves depositing a thin lipid film on a conducting
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1. Lipid suspension 
2. Dried Lipid Film
ITO slide
ITO slide
ITO slide
GUV
3. Vesicle budding in the presence of 
    a/c voltage
Figure 2.5 – Schematic representing the electroformation of GUVs. The lipid solution
is spread on an ITO slide and left in a vacuum dessicator to evaporate the organic
solvent − this produces a multilamellar lipid film on the ITO slide. The lipid film is
then hydrated with a suitable aqueous buffer. The application of an alternating electric
field causes the lipid film to bud off the ITO surface, encapsulating the solution thus
forming vesicles.
surface, typically an Indium Tin Oxide (ITO) slide. A sandwich of two ITO slides
is made, with the conducting surfaces facing each other, and a desired solution filling
the gap between the slides. The application of an a/c voltage across the two conducting
surfaces causes the lipid film to bud off, encapsulating the solution thus forming vesicles
(Figure 2.5).
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Electroformation has been the method of choice for GUV formation since its in-
troduction by Angelova and Dimitrov [36], and we therefore settled on it for the
purposes of our work. Besides their ease of observation, they are formed quickly
(within 2-3 hours) and the vesicles formed are mostly unilamellar, and of good quality
[37]. Indeed, such is the popularity of electroformation that it has even spawned the
production of a commercial bench-top setup, the Nanion Vesicle Prep Pro (Nanion
Technologies GmbH, Germany), that simplifies the experimental protocols involved.
However, it must be noted that the actual process of electroformation is not well
understood, and optimising the experimental protocol can prove challenging. This lack
of understanding means that we have little control over the size range of the vesicles
produced, which we need to correct for in our analysis. Moreover, electroformation
in the presence of physiological salt concentrations is difficult [38], which limits the
range of solutions that can be studied. However, notwithstanding these limitations,
electroformation provided us with vesicles that were suitable for use in our assay and
was the method employed by us for all the relevant experiments in this Thesis.
2.1.5 Overton’s Rule
Theoretical studies of the permeability of cell membranes date back to the end of the
19th century. In 1899, the physiologist and biologist Charles Ernest Overton published
a beautifully simple model predicting the permeability of biological membranes to a
range of molecules [39]. He concluded that the entry of molecules into cells was gov-
erned by their “selective solubility” in the cell boundary [39]. Even more importantly,
he predicted that the permeability of a molecule is a function of how soluble it is in
lipids − the greater the lipid solubility, the higher the permeability. This concept has
since been termed ‘Overton’s Rule’ [39]. Remarkably, over a century of experimental
investigations into lipid permeability have confirmed that Overton’s Rule still rules
[39, 40].
The rule stipulates that the transmembrane flux density (J ) of a membrane-permeating
molecule can be predicted if one knows its partition coefficient (K ) from an aqueous
into an organic phase [40]. Fick’s law of diffusion can thus be rewritten as [15, 40]:
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J = −Ddcm
dx
= −D
(
c1m − c2m
d
)
= P (c2w − c1w) (2.2)
where D is the diffusion coefficient of the molecule in the organic phase, c1m and c2m
the concentration of the molecule at the two interfaces of the organic phase, c1w and c2w
the corresponding molecule concentrations at the interfaces of the aqueous phase and
d is the membrane thickness. P ≡ KD/d is defined to be the permeability coefficient
of the molecule across the membrane.
Over the past century, thousands of compounds have been tested, out of which only
a tiny proportion show deviations from the rule [40]. The observed deviations are
believed to be the result of transient defects in the membrane, with the proton being
the most prominent example of substances belonging to this group [40]. It is important
to clarify here that the rule only applies to simple lipid membranes − work over the
past century has elucidated that true biological membranes have a range of protein
pores in them, which facilitate membrane transport. In fact, Overton even predicted
that ions would have to use a different pathway to enter cells, since the low dielectric
constant of lipids prevented the solvation of charged particles [39].
However, the basic premise linking lipophilicity to membrane permeability still holds
true, and is the foundation for the use of partition coefficients in the pharmaceutical
industry. What we intend to do in this Thesis is develop a technique to measure
the permeability of a molecule directly, without requiring knowledge of the partition
coefficients, which can be difficult to measure in lipids. The intention is to directly
measure the permeability of the molecule of interest across the lipid membrane of
interest, rather than having to worry about which organic phase to use to model the
lipid bilayer. We shall show how the use of specific lipids influences drug permeation,
hence demonstrating why it is not advisable to use simple octanol partition coefficients
to estimate drug permeability. Importantly, our technique will also enable us to study
the influence of passive diffusion pores on drug permeation, and thus will provide a
platform for investigating drug transport mechanisms in more detail than is typically
the case.
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2.2 Microfluidics
Microfluidics, as its name implies, refers to the technology of systems capable of ma-
nipulating small (10-9− 10-18 litres) quantities of fluid using channels with dimensions
of tens to hundreds of μm [41]. Besides offering precise control over fluid flow and
mixing, all flows at such lengthscales are laminar, offering novel ways of controlling
molecule concentrations in space and time [41]. The laminar flow patterns are a
consequence of the low Reynolds number (Re) associated with microfluidic flows −
Re is a dimensionless quantity that characterises the relative strength of inertial and
viscous forces acting in a fluidic system. In microfluidic devices, viscosity dominates
and laminar flows are the norm [41]. Fluid mixing is thus governed by diffusion, and
depending on the flow velocities and the diffusion coefficient of the substances being
mixed, one can predict the degree of mixing between flows at different points in a
channel. In addition, small sample volumes, low cost, high-throughput capabilities and
controlled microenvironments have made microfluidic technologies applicable across a
wide range of fields [41–44].
Figure 2.6 – A typical microfluidic device. This particular chip is used to study the
growth of microbial populations. The channels are visualised here by passing dyes of
different colours through the device. Pictured next to a 1 Dime coin (USA) for scale;
the coin is 18 mm in diameter. Image taken from [45].
In medical diagnostics, for example, microfluidic devices are replacing conventional
tests, enabling point-of-care diagnostics outside specialised laboratories. TheWhitesides
lab has pioneered the use of paper based microfluidic devices which are cheap, easy to
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store and transport, and hence ideal for use in low-resource settings [46]. The use of low
sample volumes is an added attraction − finger-pricks strike significantly less fear into
people as compared to normal blood draws. Microfluidics allows one to perform many
different diagnostic tests with just a few drops of blood, as opposed to the sometimes
tens of millilitres required for conventional blood tests. Rapid colorimetric assays will
also allow doctors to perform these tests during clinic visits, thus making the entire
system more efficient.
In drug design and discovery, the use of small volumes allows for the testing of valuable
chemicals that are not mass produced. In vitro assays to test the efficacy of drugs can
be conducted on a single cell basis with high throughput, while still using low sample
volumes.
In biomedical and molecular biology research, microfluidic devices are being used to
perform studies on the single cell level, as opposed to bulk measurements that have
for decades been the mainstay of the fields [47, 48]. Cellular heterogeneity is now
finally open to detailed, microscopic investigation, and microfluidic assays are already
revealing insights into a variety of biological processes [49–52].
2.2.1 Microfabrication Techniques
An important precursor to the development of microfluidics was the development of
microfabrication techniques for constructing the devices with suitable spatial resolu-
tion. Photo- and soft lithography played a crucial role, and the polymer polydimethyl-
siloxane (PDMS) became the material of choice for testing and designing microfluidic
chips [53]. PDMS is an optically transparent, silicone based polymer that is permeable
to air, thus making it ideal for biological applications. It is easy to work with and
relatively inexpensive; it is created by mixing an elastomeric component with a curing
agent, which sets when baked. It is also capable of supporting useful components such
as pneumatic valves, and has thus played a major role in the early development of
microfluidic technologies [41].
The main steps in the creation of a typical microfluidic device are represented in Fig-
ure 2.7. In the photolithography step, the chip design is printed on a photo-emulsion
film or a quartz mask; typically, the design is transparent on an otherwise opaque film.
20 Chapter 2 Experimental Design
1. Photolithography
2. Soft Lithography
3. Plasma Bonding
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Figure 2.7 – Schematic of microfabrication protocol. In photolithography, the UV
light selectively polymerises the photoresist that is exposed through the design mask
(image adapted from Dr. Stefano Pagliara, with permission). After developing the
mold, PDMS is poured onto the Si mold and baked. Once set, the PDMS chip is peeled
off the Si mold and plasma bonded to a glass coverslip. The air gaps between the PDMS
features and the coverslip form the desired microchannels.
A UV photoresist such as SU-8 is spin-coated on a silicon wafer, and then selectively
exposed to UV light through the mask. The UV light polymerises the photoresist, and
the remaining unpolymerised SU-8 is washed away by adding a chemical developer,
which further strengthens the polymerised design. The resulting silicon mold is the
negative replica of the final microfluidic chip, which is created by pouring a PDMS
mixture on the mold and baking it in an oven.
Once set, the PDMS chip is simply peeled off the mold and bonded with a glass slide
to create the microfluidic device; this is typically done by exposing both surfaces to
an air plasma to facilitate bonding. The plasma leads to the formation of silanol (Si-
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OH) groups in the PDMS at the expense of methyl groups. Since silanol groups are
polar, they make the surface highly hydrophilic, thus facilitating the filling of the chip
with aqueous solutions. When two such surfaces (either PDMS-PDMS or PDMS-glass)
are brought in contact, the silanol groups condense yielding strong Si-O-Si bonds [54].
Although other bonding techniques have been developed [55], plasma bonding remains
a very effective technique that provides a tight seal between the PDMS chip and glass.
A strong seal is obviously crucial for any microfluidic device, in order to prevent fluids
from leaking out of the microchannels, and we therefore used plasma bonding for
creating all the microfluidic devices mentioned in this Thesis.
2.2.2 Vesicle based microfluidics
Transport studies involving vesicles in microfluidic devices have been performed re-
cently in the group of Prof. Petra Dittrich in ETH Zurich. Her team has developed
microfluidic platforms that immobilize vesicles using both physical [56] and chemical
[19] trapping. The physical trapping technique used a PDMS chip with 60 chambers,
in which GUVs were trapped hydrodynamically in between posts. The technique
included the use of valves, which could isolate a trapped vesicle from the rest of the
fluidic network. Solution exchange was possible without disrupting the vesicles, and
GUVs remained stable over long periods (>12 hours) [56]. The technique was used
to study the transport of the fluorescent dye calcein through the protein pore alpha
hemolysin reconstituted in the vesicles.
For chemical trapping, small unilamellar vesicles (diameter ∼ 180 nm) were immo-
bilized on a glass slide using avidin- and PEG(polyethylene glycol)-biotin bonds. The
transport of the antibiotic tetracycline into these vesicles was observed by the formation
of fluorescent complexes of the drug with salts enclosed in the vesicles [19].
Both these techniques involve the immobilization of vesicles in the chip, and this
naturally limits the experimental throughput. Furthermore, fluorescent reporters were
required to detect the uptake of tetracycline. However, these techniques show that it
is possible to use vesicles for transport studies in microfluidic environments, and with
this in mind, we went on to develop our own vesicle based microfluidic assay. The
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experimental detail is provided in the next section, and the next two chapters of this
Thesis will be devoted to some of the results we have obtained using this technique.
2.3 The Optofluidic Permeability Assay
2.3.1 Optical Setup
Figure 2.8 – Schematic of Optical Setup. Broadband white light is passed through a
monochromator which selects the fluorescence excitation wavelength (340 nm). The
excitation light is directed onto the microfluidic device and the emitted fluorescent
radiation is focussed onto an EMCCD camera. Suction is applied at the outlet of the
microfluidic network with a syringe pump.
The optical setup is a custom built UV epifluorescence microscope described schemati-
cally in Figure 2.8. The output from a broadband white light source (EQ99FC, Energe-
tiq, USA) is passed to a monochromator (Monoscan 2000, OceanOptics, USA) which
selects the desired excitation wavelength (340 nm) and directs it onto the microfluidic
device via a Köhler illumination pathway and a suitable dichroic mirror (DLHS UV
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351-355, Qi-Optiq, Germany). The objective used is a 60× water immersion UP-
LSAPO Olympus objective (NA 1.2). The emitted fluorescent light passes through the
dichroic and is focussed onto the detector, an EMCCD camera (Electron Multiplying
Charge Coupled Device Evolve 512, Photometrics – exposure time 2 ms, bin 2, EM
gain 100, frame rate 65 fps) via a tube lens and a mirror. All lenses used (apart from the
objective) are made from UV fused silica to optimise UV transmission and the optical
fibers are UV grade (OceanOptics). The camera is controlled using the open-source
software μManager 1.4 [57].
As we shall see later, it is possible for some of these experiments (with norfloxacin,
for example) to be performed using commercial microscopes with suitable UV light
sources and filter sets (for norfloxacin, a standard DAPI filter set works well). However,
for applications which require deep UV transmission, it will be necessary to replace the
optics in a commercial setup with quartz optics.
2.3.2 Microfluidic Chip Design and Fabrication
The microfluidic chips used in the assays were produced using standard photo- and soft
lithography techniques [53, 58]. Three different chip designs were constructed, whose
exact details can be found in appendix B. The channels are 40 μm wide. The basic
principle of all three devices is the same, and is depicted in the schematic (Figure 2.9).
A microfluidic T junction enables the mixing of two different solutions (the lipid
vesicles and the drug) in a long channel. The main difference in the three chips is
the length of this mixing channel − in the ‘Long’ design, the total length from the T
junction to the outlet reservoir is about 380 mm. In the ‘Medium’ it is 127 mm and
in the ‘Short’, just 28 mm. The different lengths were created to enable the study of
membrane transport processes that occurred over different timescales. The ‘Short’ chip
is designed for studying drug uptake which occurs in a matter of seconds − therefore
here the initial viewpoint is almost immediately after the T junction. In the other
devices, the initial viewpoint is about 15-20 seconds post flow mixing − this ensures
that the drug/particle being studied has diffused across the entire width of the channel
before the vesicles are imaged for the first time. Though not critical for the norfloxacin
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measurements, this extra length is required when studying larger molecules/particles
which have smaller diffusion coefficients.
t = 0 t = tf
40μm
Vesicle Inlet Drug Inlet
Outlet
L1
L2
L3
L = Distance from 
t = 0 to t = tf 
detection point 
40μm
Figure 2.9 – Schematic of microfluidic network. The inset displays a typical flow
pattern at the T junction in an experiment, illuminated in combined brightfield and
fluorescence mode for clarity. Lipid vesicles are exposed to a uniform concentration of
the drug along the network. The t = 0 point is chosen after the drug has equilibrated
across the channel width. Vesicles at t = 0 and later time points are observed in the same
field of view. The two observation points are a length L apart along the network. As
vesicles progress along the network, if the drug is permeable, the fluorescence intensity
inside the vesicles increases.
In all the designs, the channel is constructed such that it loops around multiple times
(Figure 2.9). This allows the detection of vesicles at two distinct time points in the same
field of view (at 60× magnification). By imaging vesicles at different positions in the
chip, one can study the time dependence of drug uptake. We also included a network
of pillars in the inlet reservoirs as filters to prevent large lipid aggregates from entering
the microfluidic network and blocking the flow. There are two sets of pillars− a coarse
filter with 75 μm gaps, and a fine filter with 40 μm gaps (appendix B).
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Photolithography of the Si molds2
The masks were designed in AutoCAD and printed on emulsion film ( JD Photo-Tools
UK). SU-8 3050 (Chestech UK) photoresist was spin coated (SCS Spincoat G3P-8, 7s
at 500 rpm followed by 30s at 3,000 rpm) onto a Si wafer (Microchemicals, Germany)
and then baked on a hot plate (96 oC for 20 mins). After aligning the desired film mask
on the wafer, it was exposed to UV (the UV lamp was an OAI system with an output
power of 200 W) for 15 seconds, post-baked for about 6-7 mins at 96 oC and then
developed in Propylene glycol monomethyl ether acetate (PGMEA) for approximately
10 mins. This was then rinsed with isopropanol and blow dried with N2. The protocol
led to the formation of channels with a height of 50 μm.
Soft Lithography for constructing the PDMS chip
A negative replica of the desired Si mold is obtained using Sylgard 184 Polydimethyl-
siloxane (PDMS − from Dow Corning); a 9:1 ratio of elastomer:curing agent PDMS
mixture is poured onto the Si mold and cured for 55 mins at 60 oC in an oven. This is
then carefully peeled off the Si mold and cut into a desired shape using a sharp blade.
The inlet and outlet holes are punched using a 1.5 mm biopsy punch. It is important to
clean the punched columns and the rest of the PDMS chip with 96% ethanol (it must
then be dried gently with N2). Finally, the PDMS chip is bonded to a glass coverslip
(Type 1, Assistent, Germany) by exposing the surfaces being bonded to an air plasma
(10 W plasma power, 10 s exposure, 25 sccm, plasma etcher from Diener Electronic
GmbH & Co. KG, Germany) and then binding the two exposed surfaces together to
create a sealed microfluidic device. This is placed in an oven at 60 oC for 10 mins to
enhance the adhesion. The chip should be filled with the buffer/water within 10-15
mins after construction so that the channels wet easily − the plasma bonding makes
the channels temporarily hydrophilic, and this property must be exploited. Once the
chip is filled and checked to ensure there are no air bubbles, the device is ready for use.
2The ‘Short’ design Si mold was constructed by Dr. Stefano Pagliara, whose photolithography
protocol differs slightly from mine. This additional protocol is provided in appendix B.
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2.3.3 Vesicle electroformation protocol
GUVs are created by electroformation using a Nanion Vesicle Prep Pro setup. Fig-
ure 2.10 depicts some typical GUVs obtained with this protocol.
50 μm
Vesicle (in focus)
Vesicle (out of focus)
Lipid
aggregates
Figure 2.10 – Typical GUVs obtained after electroformation. Imaged under brightfield
with 20x magnification. The heterogeneity of results obtained via electroformation is
seen. Since there is no difference in solutions between the interior and exterior of the
GUVs, they can float in solution; therefore the two GUVs seen here are not in the same
focal plane. We also observe lipid aggregates after electroformation, and have built in
safeguards in our analysis to separate these from vesicle detections.
60 μl of 5 mg/ml 1,2-diphytanoyl-sn-glycero-3-phosphocholine (DPhPC) lipid (Avanti
Polar Lipids) in chloroform is spread on the conducting surface of an ITO coated glass
slide (Nanion/Visiontek) within a rubber O-ring. The chloroform is evaporated for
10 mins in a desiccator following which 600 μl of the appropriate buffer (200 mM
sucrose in a 5 mM phosphate buffer for pH 7 or 200 mM sucrose in a 5 mM acetic
acid buffer for pH 5) is deposited within the O-ring and a sandwich made with another
ITO coated slide (conducting surfaces facing each other). This is placed in the Nanion
Vesicle Prep Pro whereupon electroformation proceeds in 3 steps: (i) The a/c voltage
increases linearly from 0 to 3 V peak to peak (p-p) at 5 Hz in 5 mins. (ii) The voltage
stays at 3 V p-p and 5 Hz for 2 hrs. (iii) The voltage decreases linearly to 0 V at 5 Hz
in 5 mins. The electroformation was carried out at 37.5 oC. The vesicles were stored
at 4 oC and used within a week. This formation protocol was used for all the vesicle
experiments in this Thesis.
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2.3.4 Microfluidic flow control
200 μm Vesicle
Typical viewpoint
Figure 2.11 – Snapshot at the T junction of the ‘Short’ microfluidic chip in action,
using a 10× objective on a commercial Olympus IX73 microscope. Norfloxacin
fluorescence is excited using an arc lamp and a DAPI filter set. For data collection,
as mentioned earlier, 60× objectives are used.
The microfluidic flows are controlled by applying suction at the outlet reservoir using
a neMESYS syringe pump system. In early experiments, a 1 ml Duran Borosilicate
glass syringe (ILS, Germany) was used. However, it was observed that syringes with
lower volumes provided better flow control, and were less susceptible to air bubbles.
The optimum syringe volume for our experiments was found to be 250 μl, and hence
most experiments were carried out with a 250 μl Duran Borosilicate glass syringe (ILS,
Germany). The volume of the syringe should be chosen such that it exceeds the
volume of the tubing used to connect the syringe to the microfluidic chip; this helps in
removing air bubbles when filling the syringe and tubing with solutions before starting
the experiment. The tubing used was Upchurch 1520G (0.03 inch inner diameter). At
the inlets, pipette tips with 50 μl of vesicle stock solution and 50 μl of 2 mM norfloxacin
solution respectively were input into the two reservoirs, using a previously described
technique [59]. Initially, to ensure a uniform distribution of norfloxacin throughout
the network, a fast flow (30-100 μl/hr) was applied. Once the fluorescence intensities
were observed to be uniform in the detection regions, the flow rate was decreased to
about 3 μl/hr. Data collection was started once the flows settled and individual vesicles
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were slow enough (∼1 mm/s) to be tracked in the field of view for about 5-10 frames to
ensure a reliable statistical analysis of the relevant measured quantities. It is important
to note that we study individual vesicles as they pass through the network − this is not
a bulk experiment − with a throughput up to 100 vesicles per hour.
A detailed experimental protocol for this assay is provided in appendix A. A typical
snapshot (zoomed out) of the experiment in progress is depicted in Figure 2.11.
2.3.5 Diffusion model for calculating drug permeability
Iout,cout
Rin
Rout
d
Iin,cin
r
I = Autofluorescence Intensity
c = Drug concentration
Giant Unilamellar Vesicle
Figure 2.12 – Schematic of a Giant Unilamellar Vesicle.
A giant unilamellar vesicle created by electroformation is shown schematically in Fig-
ure 2.12. A lipid bilayer separates the interior from the exterior of the vesicle. Autoflu-
orescence intensities within the vesicle Iin are related to the concentration of the drug
inside the vesicle cin.
Preliminary confocal measurements on vesicles suspended in a bath of norfloxacin
proved that although the concentration of norfloxacin that is diffusing into the vesicles
(cin) is dependent on time, its spatial concentration within the vesicle is uniform [13,
60]. The norfloxacin diffuses almost instantaneously (within a second) across the
volume of the vesicle.
2.3 The Optofluidic Permeability Assay 29
Thus the rate limiting step in the diffusion process is membrane permeation. The flux
of norfloxacin molecules passing through the membrane at a given time t is thus given
by [13]:
J(t)
4pir2
= −KDdc
dr
(2.3)
which on integration gives:
J(t) = 4piRinRout
KD
d
(cout − cin(t)) (2.4)
where D is the diffusion coefficient and K the partition coefficient. The drug concen-
tration outside the vesicle cout stays constant over time. Since the thickness (d) of the
bilayer ( ∼ 5 nm [61]) is 3-4 orders of magnitude less than the radius (R) of the vesicles
being considered, we may assume that the inner and outer radii are the same, i.e, Rin∼
Rout= R.
The flux of particles passing through the membrane per unit time also equals the
variation in the number of particles trapped inside the vesicle. Since within the vesicle
the norfloxacin concentration is homogeneous, we can write:
J(t) =
dcin(t)
dt
(
4piR3
3
)
(2.5)
Equating the two equations gives:
dcin(t)
dt
=
3KD
Rd
(cout − cin(t)) (2.6)
Solving this with boundary conditions:
• cin(t = 0) = 0
• cin(t = tf) = cin(tf)
and using our definition of the permeability coefficient P ≡ KD/d, we obtain the
solution:
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P = −
(
R
3t
)
ln
(
cout − cin(t)
cout
)
(2.7)
We thus have an equation for the permeability coefficient P, our quantity of interest.
However, we need to adapt this equation based on our experimentally measured pa-
rameters. In our experiment, we measure the autofluorescence intensities within the
vesicles (Iin) at different time points, the background autofluorescence intensity of the
drug (Iout), the radius of the vesicle (R) and, indirectly (by measuring vesicle velocity),
the time (t) taken for the vesicle to move between detection positions.
Let us examine our equation for P in a little more detail before proceeding. We detect
the vesicles at different points, and use the flux of drug molecules into the vesicle in
the intervening time to determine P. Hence, it should be obvious that the time t in the
equation cannot be zero, since one cannot measure a buildup of drug molecules in a
vesicle at just one time point. In any case, the mathematics also tells us that as t goes
to zero, cin (t) also goes to zero and the equation is satisfied. One must recall that, even
though we are using the change in drug concentration inside the vesicle to measure the
permeability, P is a physical constant for a given drug-lipid combination.
Furthermore, we have assumed in our model that the drug equilibrates within the
vesicle as soon as it is past the membrane barrier. In practice of course this cannot
be the case, and the drug molecules will take a finite amount of time to diffuse in the
vesicle volume. A rough estimate for a vesicle with a radius of 10 μm reveals a diffusion
timescale on the order of 50-100 ms for norfloxacin, which is well below the timescales
that we analyse. Similarly, in the long time limit, cin will exponentially converge to cout,
and again the formula holds true.
Let us now look at our equation in terms of the parameters that we actually measure in
the experiment. The drug concentration outside the vesicle is directly proportional to
the fluorescence intensity Iout. However, since the optical setup used in the microfluidics
experiments is not a confocal microscope, the drug concentration inside the vesicle
(cin(t)) depends on the fluorescence intensity inside the vesicle Iin in a more complicated
manner. We can split the intensity contribution inside the vesicle into two parts, one
that is the contribution of the drug (Itruein(t)) and another that is simply due to the out
of focus light from outside the vesicle that has entered into the region being studied,
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that we label F. F is independent of time (since it is independent of drug concentration)
but has a dependence on the vesicle radius. Now,
cout − cin(t)
cout
=
Iout − I truein (t)
Iout
(2.8)
We detect vesicles at an initial point that we define as t = 0 and at a later time point t =
tf . Vesicle detection is performed in a two-step process during image processing3:
• Firstly, deviations from the mean image intensity are detected, and if the differ-
ence from the baseline is more than a suitable multiple of the median absolute
deviation (MAD), the frames are considered for potential vesicle detections. This
condition may be varied depending on the SNR of the experiment. Initially, we
used 3×MAD as our criterion, but noticed that we were then missing a significant
fraction of events. We therefore reduced this to just 1×MAD for the home-built
setup.
• Secondly, the vesicles are identified in each of the candidate regions. A back-
ground is calculated as the averages of the frames just before and after each de-
tection event. This background is then subtracted from each of the images in the
candidate region in order to enhance the vesicles, as they are the main source of
intensity variation. A binary mask with the vesicle outline is obtained using the
threshold given by the Otsu method.
• Finally, the ‘regionprops’ function in MATLAB is used to obtain information
about the major and minor axes, the centre of the shape, amongst other param-
eters. The vesicle radius is determined by taking an average of the semi-major
and semi-minor axes. Since we capture the vesicles for multiple frames, we can
track the movement of the centre position and use this to determine the vesicle
velocity. Around the centre, a 5×5 pixel box is created and the average intensity
within this box is determined. The average intensity of exactly the same 5×5
pixel box is determined in the background image for each event. This gives us the
values of Iin and Iout, which are used in the calculations.
3The MATLAB programs were written in collaboration with Dr. Avelino Javer (formerly of the
Cicuta group, Cavendish Laboratory).
32 Chapter 2 Experimental Design
For clarity, let us introduce the convention that all intensities related to the interior of
vesicles (Iin) at the initial detection point t = 0will be denoted as I(0) and at later times as
I (t). We reiterate that the intensities outside the vesicles Iout remain constant with time,
and will always be written as Iout. Our image analysis program outputs the following
value for each vesicle at the two time points:
∆I(0) =
Iout − I(0)
Iout
(2.9)
∆I(t) =
Iout − I(t)
Iout
(2.10)
Now,
I0 = I
true
0 + F = F (2.11)
since we assume that the drug concentration inside the vesicle is 0 at t = 0. Further-
more,
I(t) = I
true
(t) + F = I
true
(t) + I(0) (2.12)
Therefore,
I true(t) = I(t) − I(0) = I truein (t) (2.13)
Thus,
cout − cin(t)
cout
=
Iout − I truein (t)
Iout
=
Iout − (I(t) − I(0))
Iout
= ∆I(t)+
I(0)
Iout
= ∆I(t)+1−∆I(0)
(2.14)
Substituting this in our equation for P equation (2.7), we finally obtain:
P = −
(
R
3t
)
× ln(∆I(t)−∆I(0) + 1) (2.15)
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This is the equation we use to calculate the permeability coefficient for individual
vesicles. As mentioned in the discussion above, this model is applicable when the time
between detection points is greater than about 100 ms. However, we should also note
that our experimental resolution fixes a finite upper bound on the time differences
as well. As the time between the detection points increases, ΔI(t) becomes smaller
and smaller as the drug concentration within the vesicle approaches the external con-
centration. ΔI(t) will approach zero exponentially, but our measurement timeframe
depends on our detector being able to distinguish the vesicle from the background
via its intensity contrast. Therefore, in practice there is also an upper bound on the
timeframes that can be studied, which depends on the speed of drug uptake and also on
the vesicle radius.
However, using our microfluidic approach, hundreds of vesicles can be detected and
analysed with this equation within the experimental timescales. In the following chap-
ters, we shall apply this technique to the study of passive norfloxacin transport across
phospholipid bilayers. In addition, we perform measurements with different antibiotic-
lipid combinations, and show how the same detection technique can be extended to
studying the interaction of other nanoparticles with lipid membranes.
2.3.6 Data Analysis
We have two MATLAB analysis codes; the first studies the images in the TIFF stacks
obtained (the raw experimental data) and obtains all the desired information on a frame
by frame basis. We then process this data set with a ‘post-process’ code that averages
all the relevant values on a vesicle-by-vesicle basis. Thus, if a single vesicle is detected
for, say, 10 frames, the values of ΔI and R will be averaged over the values in all 10
frames − it is this average value that is used in the calculations. Furthermore, the first
code measures the minor and major axes of the vesicles on a frame by frame basis, and
reports a circularity criterion defined as:
Circularity =
MinorAxis
MajorAxis
(2.16)
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The theoretical analysis is based on the vesicles being circular. Therefore, we apply a
filter in the post-process code that deletes all vesicles detected with a circularity lower
than a defined value (the optimum value for this filter was found to be 0.7, although
0.75 can also be used). The code also tracks the centre position of each vesicle. The
post-process code uses this information (and a knowledge of the camera frame rate) to
determine the vesicle velocity. A knowledge of the chip geometry and vesicle velocity
determines the time t taken by the vesicle to travel the intervening distance between
two detection points.
The final analysis is performed manually with OriginPro software. In addition to
the circularity filter, at this stage filters are applied on the radius and vesicle velocity
which help avoid the detection of false positives generated due to the detection of
lipid aggregates. With regards to the radius, the width of the microfluidic channel is
40 μm. Therefore, vesicles with radii greater than 20 μm are discarded − these are
prone to shear by the channel walls. It was also observed that detections with radii less
than approximately 8.5 μm were often due to lipid aggregates, and were thus discarded.
When considering vesicle velocities, experience showed that if the velocity was less than
∼0.4 mm/s, the detected objects were either vesicles rolling along the channel walls (in
which case they were prone to shear) or lipid aggregates. Velocities above 1.5 mm/s
were almost always small lipid aggregates, and not vesicles. The events were filtered
accordingly.
At the different vesicle detection points, there might be slight changes in the measured
vesicle radius due to optical or fluidic effects. However, our calculation relies on R
being unchanged for the measurement of ΔI(0) and ΔI(t). To solve this problem,
we plot ΔI(0) vs R (for a typical example, see Figure 2.13) and use the resultant
linear relation as a calibration for ΔI(0). The linear relation between ΔI and R is a
direct consequence of the imaging technique being a brightfield rather than a confocal
measurement (for details, please refer to appendix C). Now, for all the vesicles detected
at the later detection point, we measure the radius, and use this value of R to obtain
a corresponding ΔI(0) value from the calibration plot. It is this ‘recalculated’ value of
ΔI(0) that is used, along with the radius measured at the later detection point, in the
equation for permeability above (equation (2.15)).
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Figure 2.13 – Typical calibration plot ofΔI(0) vs R. This linear fit is used to recalculate
ΔI(0) for vesicles using the radius measured at time t (the final detection point). This
‘recalculated’ ΔI(0) is used in the calculation of the permeability coefficient using
equation (2.15).
We thus have all the quantities required to determine the permeability coefficient of
each vesicle to the drug under investigation.
It should be mentioned here that the MATLAB code separately saves the frames (from
the original image stack) in which vesicles are detected. This allows us to visually check
the raw images corresponding to a data point on the scatter plot (of course, it is possible
to find the same vesicle in the original video, but that would be rather more tedious).
This acts as a further check that can be used to weed out false positives.
2.4 Conclusions
We have thus set up a novel, label-free technique of studying passive drug transport
across lipid membranes that directly determines drug permeability coefficients using
lipid vesicles. It is experimentally simple and can be adapted for cell work. The
experiment itself is robust and can be run for hours at a stretch; it is thus capable
of generating a much higher throughput than older vesicle-based techniques. It can be
used to study passive transport in membranes of varying lipid compositions and also
to study the effect of membrane-bound transporters on drug transport. In the next
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chapter we shall discuss the use of this technique to study the permeability of drugs
and nanoparticles through pure phospholipid membranes, before moving on to the
investigation of pore mediated drug transport in chapter 4.
Chapter 3
Transport Across Pure Phospholipid
Membranes
“There is a tide in the affairs of men, which taken at the flood, leads on to
fortune.”
Brutus (The Tragedy of Julius Caesar)
3.1 Introduction
In this chapter, we shall apply our new technique to the study of antibiotics and other
nanoparticles as they diffuse across pure phospholipid membranes. The technique was
validated by studying the transport of norfloxacin across DPhPC vesicle bilayers, and
we shall begin with a description of the results and analysis of this system. One major
advantage of this technique is that the lipid membrane composition can be changed
easily−we shall show that changing the type of phospholipid in the vesicle membranes
can have dramatic effects on the permeability of norfloxacin.
To demonstrate the versatility of the technique, measurements were also performed
using a different class of antibiotics. The permeability of a broad spectrum polyketide
antibiotic, tetracycline, is investigated, thus showing that the technique is not limited to
fluoroquinolone antibiotics. Finally, the interaction of nanoparticles such as Quantum
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Dots (QDs) with lipid membranes is an important field of study, especially in light
of concerns raised about the toxicity of nanoparticles and their accumulation in cells.
QDs are also autofluorescent in the UV, and we report some measurements on the
interaction of Cadmium Selenide QDs with DPhPC lipid vesicles.
Before reporting these results, we shall briefly introduce some basic concepts about the
phospholipid bilayer.
3.1.1 Phospholipid Bilayers
Polar (Hydrophilic)
Non-polar
(Hydrophobic)
Polar (Hydrophilic)
Figure 3.1 – The Phospholipid Bilayer.
The cell membrane of almost all biological organisms contains, as its core foundation, a
double layer of lipid molecules. The most commonly found, naturally occurring lipid
molecules are the phospholipids. These are amphipathic molecules, which contain a
polar (hydrophilic) head group and two non-polar (hydrophobic) hydrocarbon chains.
When suspended in an aqueous solution, the amphipathic character of these molecules
governs their self-assembly; the polar headgroups preferentially align to remain in
contact with the aqueous phase, whereas the hydrocarbon chains do all they can to
avoid the polar water molecules. This inevitably leads to the formation of lipid bi-
layers (Figure 3.1), where the lipid molecules pack together in their energetically most
favourable configuration− polar groups on the outside, non-polar chains on the inside.
The non-polar core of lipid bilayers is crucial − this is what keeps polar molecules and
ions from flooding the cell and causing osmotic shock. It is central to the so-called
‘semi-permeability’ of cell membranes. Besides acting as a barrier, the lipid bilayer also
behaves as a solvent for the numerous membrane spanning proteins that catalyze the
transport of ions and molecules across the lipid permeability barrier [62]. Studies on
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the permeability of small molecules across lipid bilayers have concluded that water and
non-electrolytes cross the barrier via the solubility-diffusion mechanism predicted by
Overton, and also conclude that the bilayer barrier (i.e, excluding the headgroups) may
be approximated as a thin sheet (∼3 nm thick) of liquid hydrocarbon [62, 63].
Phospholipids always contain a phosphate moiety in the headgroup, but otherwise may
possess a variety of different headgroups and hydrocarbon chain lengths. Considerable
effort has been expended on the study of phospholipid bilayers, in order to better un-
derstand their role in cellular membrane transport. Their interaction with membrane
proteins is another major avenue of research, and we shall discuss one such process of
protein mediated membrane transport in chapter 4.
Of the various types of phospholipids, the phosphatidylcholines (PC) were amongst
the first to be discovered. These form amajor component of cellular membranes and are
routinely used to form artificial bilayers. We developed our technology using this class
of phospholipid, and shall introduce some of its properties in the following section.
3.1.2 Phosphatidylcholine lipids
Phosphatidylcholine (PC) lipids are phospholipids that contain choline as a headgroup.
PC is an essential phospholipid in mammalian cells, and is made in all nucleated cells
via the choline pathway [64]. It is the major structural component of eukaryotic cell
membranes, and also plays an important role in lipid mediated signal transduction
[65, 66]. Although less common in prokaryotes, it is estimated that more than 10%
of all bacteria contain PC as a membrane phospholipid [67]. PC lipids in bacteria
are generally formed by the enzymatic methylation of the commonly found phos-
phatidylethanolamine (PE) class of phospholipids, although choline dependent path-
ways for PC production have also been reported [67].
The PC lipids found in biological membranes also tend to form lamellar phases (bilay-
ers) in water over a wide range of temperatures [68]. This makes them suitable for use
in the formation of giant unilamellar vesicles, our model system. Thus PC lipids are
both biologically interesting systems to investigate and convenient lipids to work with,
making them an obvious choice for our assay.
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We chose to work primarily with the artificial PC lipid DPhPC. This phospholipid
molecule is commonly used to form artificial bilayers since it can be produced syn-
thetically and hence free of impurities. Furthermore, it is known to form very stable
bilayers and is not autoxidizable [69]. The high degree of stability arises from the fact
that the hydrocarbon chains in DPhPC are composed entirely of saturated bonds [70].
Since DPhPC bilayers show very low ion leakage, they have been the lipid bilayers of
choice for studying lipid-protein interactions; they have been used extensively for the
study of membrane channel activity [71].
3.2 pH dependence of norfloxacin transport
3.2.1 Norfloxacin charge dependence on pH
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Figure 3.2 – pH dependence of norfloxacin charge. Isoelectric point 7.37. Source:
www.chemicalize.org
Norfloxacin, along with other fluoroquinolones, contains two proton binding groups.
The first, with a pKa value of 6.34, is the 3-carboxyl group and the other, with a pKa
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of 8.75 (PubChem data), is the outer nitrogen on the piperazine substituent [72]. The
multiple protonation sites indicate that the norfloxacin molecule can exist in different
charge states. A detailed analysis based on microscopic dissociation constants predicts
that at physiological pH values, a significant proportion of the norfloxacin molecules
exist in their uncharged state, whereas at acidic pH values the molecule is protonated
and has a net positive charge [72]. More precisely, at pH 7.4, the molecules are gen-
erally zwitterionic, but approximately 10% of the molecules are uncharged and it is
these uncharged molecules that are expected to contribute to the passive diffusion of
norfloxacin across lipid bilayers [72, 73]. The predicted pH dependence of norfloxacin
charge is summarized in Figure 3.2. As discussed earlier, polar charged molecules
have very little affinity for the non-polar core of lipid bilayers. We would therefore
expect the permeability of the uncharged form of norfloxacin to be significantly greater
than its charged, protonated form. We can thus use the charged form as an effective
control experiment, to test whether our vesicles are prone to leakage in the flow system
developed.
3.2.2 Calibrating the autofluorescence on our microscope
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Figure 3.3 – Fluorescence intensity profile of norfloxacin at 340 nm excitation. Camera
EM gain 20, 2ms exposure, bin 2, clearing pre-sequence. Published in [13].
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To determine the minimum concentration of norfloxacin that could be detected by
our camera, we performed a calibration by pipetting droplets of different norfloxacin
concentrations (prepared in the pH 7 buffer used in experiments) in between two glass
coverslips. The results are shown in Figure 3.3. The droplets were suspended between
the two coverslips as measuring the intensity in a droplet simply placed on a single
coverslip is susceptible to variation due to the curvature of the droplet. The EM gain
was set at 20, to ensure that the intensity histogram peaks were in the middle of the
camera range. The minimum concentration of norfloxacin that could be detected (over
the background noise) using its autofluorescence at an excitation wavelength of 340
nm was found to be around 50 μM. As expected with an autofluorescent molecule,
the fluorescence intensity showed a linear increase with norfloxacin concentration.
Furthermore, no self-quenching was observed.
3.2.3 Results of the optofluidic assay
Preliminary single vesicle experiments implied that the time scale of norfloxacin diffu-
sion through DPhPC vesicle membranes was on the order of a few minutes at pH 7.
Furthermore, microfluidics experiments revealed a vesicle speed of 0.8-1 mm/s to be the
optimum for detection in our system. Based on these considerations, we designed the
‘Long’ chip as a network of microfluidic channels which the vesicles would take around
5-6 minutes to traverse and used this device for the norfloxacin-DPhPC measurements.
To assess the diffusion through the membrane, we measure the intensity within the
vesicles at different points in the chip. Figure 3.4 shows data for vesicles at pH 5 and
pH 7. The microscopy images show vesicles (dark) in the microfluidic channels at
different points, surrounded by the autofluorescing norfloxacin. Data is shown for two
lengths travelled, L = 45.5 mm and L = 182 mm; data for other lengths is presented in
Figure 3.5. From the images it is clear that vesicles at pH 5 remain dark as they travel
through the network, whereas at pH 7 they become progressively brighter. At pH
7, as the length travelled increases, Iin increases and there is a corresponding decrease
in ΔI. Almost no significant change is observed at pH 5 (green triangles). Thus the
autofluorescing norfloxacin permeates the membrane at pH 7 far more readily than
at pH 5. The radial dependence of ΔI at t = 0 (black squares) occurs since our
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Figure 3.4 – Norfloxacin diffusion into single lipid vesicles. Images of autofluorescent
norfloxacin diffusing into vesicles (λex = 340 nm) at pH 5 (left) and pH 7 (right). L is
the length travelled from the initial (t = 0) to the final (t = tf) vesicle detection point.
It is evident that there is an increase in the fluorescence intensities inside the vesicles
(Iin) at pH 7, and a corresponding decrease in ΔI. The decrease in ΔI is proportional
to the length (L) travelled, as seen in the plots (the difference between the black and
red points becomes larger as L increases). At pH 5, the decrease in ΔI is much less
apparent (the green and black points overlap) and Iin shows a much smaller increase
within the timescales measured. It is thus clear that the permeability of norfloxacin
through the lipid bilayer is much higher at pH 7 than at pH 5. Scale bar = 10 μm (in
all images). Each data point in the plots represents a measurement on an individual
vesicle. Published in [13].
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measurements are in brightfield rather than confocal mode; at later times, the radial
dependence is both due to this effect as well as due to drug diffusion. This was addressed
in the analysis in the previous chapter section 2.3.5.
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Figure 3.5 – Data shows that as the length travelled by the vesicles increases, Iin → Iout
at pH 7 (ΔI decreases), showing that the drug is diffusing across the lipid membrane.
This decrease is seen over a much longer time scale at pH 5. Published in [13].
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Different Analysis Techniques
Figure 3.6 shows three different techniques used to analyse the data and determine the
permeability coefficient of norfloxacin.
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Figure 3.6 –Measurements of the permeability coefficient (P). a)Dependence of Iin/Iout
with respect to the length L travelled by vesicles from the initial to the final detection
point. The solid lines are fits based on our theoretical expectation of a diffusive process
governing the transport of norfloxacin across lipid membranes. Error bars represent
standard errors of the mean. From the fit, we have extracted P = 5.2 ± 0.4×10-7 cm/s
at pH 7. b) Dependence of parameter A (defined in the figure) on 1/R. The slope
of the linear fit gives us another technique of determining P. The value obtained (pH
7) was P = 6.6 ± 0.6×10-7 cm/s. c) Histogram of P values for individual vesicles.
Values determined using equation (2.15). The average value of these single vesicle
calculations gives P = 5.9 ± 0.2×10-7 cm/s (N = 272). All reported values are mean ±
s.e. Published in [13].
The intensity within the vesicles (Figure 3.6(a)) increases as the length travelled in the
presence of the drug increases. We can use this trend to extract P. Let us first rearrange
our permeability equation (2.15) as follows:
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I(t)
Iout
= 1 +
I(0)
Iout
− exp
(
− 3Pt
R
)
(3.1)
To make this consistent with the length dependence shown in Figure 3.6, we can
explicitly relate the time (t) to the length (L) using the average velocity (va) of the
vesicles. Further, since we defined I(0) = Iin (L=0, t=0) = F and I(t) = Iin (L=L, t=tf) in
section 2.3.5, we can write:
Iin(L)
Iout(L)
= 1 +
Iin(0)
Iout(0)
− exp
(
− 3PL
va.Ra
)
(3.2)
where Ra is the average radius of the vesicles. Though Iout (L) ∼ Iout (0), they have been
written out explicitly since we measured the background intensities at both points.
Since the transport process is diffusive, we expect to see an exponential dependence of
Iin on time (and hence length L). This analysis requires values of vesicle velocity and
radius, for which the average velocity (0.81 ± 0.01 mm/s) and average radius (13.6 ±
0.1 μm) measured (pH 7) were used. Using these and the data from the exponential fit,
we obtain a permeability coefficient (pH 7) of P = 5.2 ± 0.4×10-7 cm/s.
Furthermore, since we determine the flow speed for each vesicle, we can calculate the
time taken by each vesicle to travel the length L from the initial to the final detection
point. Collating this with our measurements of ΔI and the radius of each vesicle, we
know all the parameters required to determine the permeability coefficients for each
vesicle detected using the permeability equation (2.15). Histograms of these values for
the pH 7 experiments are shown in Figure 3.6(c). The average permeability coefficient
determined is P = 5.9 ± 0.2×10-7 cm/s (N = 272). Finally, we can use the same equa-
tion to determine the permeability coefficient (pH 7) from the slope of Figure 3.6(b).
This gives P = 6.6 ± 0.6×10-7 cm/s. All values reported are mean ± s.e. Thus there is
good agreement using all three analysis techniques.
At pH 5, the majority of the norfloxacin molecules are positively charged, but at
pH 7 a significant proportion of the molecules exist in their uncharged form [72]. As
indicated in the figures, it is clear that at pH 5 fewer norfloxacin molecules permeate
the membrane. This is as expected, since polar charged molecules have a low affinity for
the non-polar core of the bilayer. This also means that the SNR for the pH 5 data is too
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low to allow the calculation of the permeability coefficient on the single vesicle level
accurately. We can estimate the permeability, however, from the trend in Figure 3.6 (a).
From our data we estimate a permeability coefficient of 0.5-1.5 × 10-7 cm/s at pH 5, a
6-fold decrease as compared to pH 7. This also confirms that our vesicles are indeed a
stable model system not susceptible to leakage.
With fluoroquinolones there is significant discrepancy among the published values of
apparent partition coefficients, and hence in the predicted permeability coefficients
[28]. Apparent partition coefficients for norfloxacin have been reported as 0 (pH 7)
[74], 0.003 (pH 7.2) [72] and 0.01 (pH 7.2) [25], which would imply a permeability
coefficient ranging from 0 to around 10-5 cm/s. Importantly, our method does not
require knowledge of the partition coefficient; we provide a direct measurement of the
permeability coefficient, and the values we obtain are well within the range predicted
in the literature [72].
We have described three ways of analysing our data to obtain the permeability coef-
ficient, to show that the norfloxacin diffusion is correctly predicted by solving our
diffusion equationmodel. Two of these techniques involve averaging over the properties
of all the vesicles and were only described to show that our model works. One of
the advantages of this technique is that single vesicles can be detected, analysed and
their norfloxacin permeability determined − the value of each vesicle’s permeability
measurement is depicted in the histogram in Figure 3.6(c) above. Thus for the rest of
this Thesis, we shall describe our results only in terms of the permeability coefficients
measured on the single vesicle level, as in the histogram above. Furthermore, since we
shall not need to discuss the length dependence further, we shall translate all future
length dependencies into time dependencies using the vesicle velocities measured.
The microfluidic flows do not affect the permeability measurement
To study any potential effect of hydrodynamics or vesicle shear on the determination
of the permeability coefficient (P), we have plotted the values of P obtained (at pH 7)
for individual vesicles against the corresponding vesicle velocities in Figure 3.7. This
includes preliminary measurements performed on stationary vesicles (N=7) in a con-
focal microscope (λex = 351 nm, red circles in Figure 3.7 − the confocal measurements
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Figure 3.7 – Plot of permeability coefficient (P) against vesicle velocity. No significant
dependence is seen, indicating that hydrodynamic effects do not significantly influence
the permeation of norfloxacin in our microfluidic environment at the relevant flow
velocities. Published in [13].
were performed by Dr. Catalin Chimerel [60]). It is clear from the plot that there
is no influence of vesicle velocity on the permeability coefficient at the relevant flow
velocities. If there were indeed an influence of hydrodynamics on drug permeation,
one would have expected to see a dependence of P on the vesicle velocity. We therefore
believe our technique and analysis to be robust in the microfluidic regime. We reiterate
here that we define a strict circularity condition to ensure that we perform the perme-
ability analysis only on vesicles that are suitably circular, and thus reject vesicles that are
damaged by shear. Besides the circularity condition, vesicles of diameters larger than
the channel width are rejected before analysis, since these are more susceptible to shear
and rupture due to contact with the channel walls. Furthermore, we are also capable of
checking the vesicles manually by viewing the raw images of vesicle detection events.
These are used to reject the few out-of-focus events that evaded our strict applicability
criteria.
3.3 Changing the lipid composition affects norfloxacin permeability 49
Summary
We have thus validated our technique of measuring the permeability coefficient of
drugs passively diffusing across lipid membranes. In contrast to previously described
methods, we do not require any labelling or chemical complex formation in order to
track the drug molecules. We further do not need to determine the drug partition
coefficients in artificial aqueous-organic phase systems; we directly obtain the perme-
ability coefficient across the membrane of interest, which is the quantity required when
designing and testing new drugs.
The rest of this chapter will describe the results obtained when applying this perme-
ability assay to a range of systems.
3.3 Changing the lipid composition affects norfloxacin
permeability
Now that we have a technique to quantify the permeability of drugs across membranes,
it makes sense to investigate what factors affect the permeability. One of the first
variables we decided to investigate was the lipid composition. Our earlier measurements
were performed using DPhPC lipid vesicles. We decided to investigate another type
of PC lipid, DOPC (1,2-dioleoyl-sn-glycero-3-phosphocholine), which has the same
headgroup as DPhPC but a different chain structure. We observe that even lipids from
the same lipid ‘family’ can have dramatically different drug permeabilities.
3.3.1 Norfloxacin transport through DOPC lipids1
To study the effect of changing the lipid composition on the permeation properties of
norfloxacin, we performed our optofluidic assay using DOPC vesicles. The DOPC
stock used was obtained from Sigma Aldrich. The vesicles were prepared in exactly
the same manner as for the earlier DPhPC experiments, in 200 mM sucrose in pH 7
phosphate buffer.
1The results from this section have been submitted for publication as a journal article.
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Figure 3.8 – Norfloxacin transport through DOPC vesicles at pH 7. a) Scatter plot
showing the rapid uptake of norfloxacin into DOPC vesicles. The black squares
reference vesicles at the initial detection point and the red circles reference vesicles
at the later detection point, about 9 s further downstream. The scatter plot shows
a considerable shift in ΔI within just a few seconds of the vesicles being exposed
to norfloxacin. Drug uptake is thus much faster in DOPC vesicles compared to
the corresponding DPhPC experiments (Figure 3.5). b) The permeability coefficient
histograms reflect this greater permeability of DOPC membranes to norfloxacin. The
average value of P was determined to be 9.4 ± 0.4×10-6cm/s (N=100, mean ± s.e), a
15-fold increase in permeability compared to DPhPC vesicles.
However, while performing the experiment it immediately became apparent that nor-
floxacin transport through DOPC was much faster than through DPhPC lipid mem-
branes. This was surprising, considering that both lipids are from the same lipid family
and differ only in the structure of their hydrocarbon tails (Figure 3.9). We therefore had
to view the vesicles within a few seconds post mixing with the drug; if we had viewed
the vesicles at the longer timescales used for the DPhPC experiments, there would have
been too little contrast in intensity between the vesicles and the background since too
much of the autofluorescent drug would have been present within the vesicles. Hence
for all fast permeation experiments, we used the ‘Short’ microfluidic chip (appendix B).
In this chip design, the initial viewing point (t = 0) is immediately after the drug and
vesicles mix at the T junction. The t = 0 point is chosen to be the earliest point
at which the norfloxacin diffuses across the entire width of the channel (as observed
by measuring the norfloxacin autofluorescence intensity profile within the channel) at
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the flow rates used in the experiment (3-4 μl/hr). The corresponding detection point
further downstream that falls in the same field of view is at a distance of 7.4 mm further
along the channel. The DOPC vesicles took, on average, 9 ± 1 seconds (mean ± s.d)
to traverse this distance.
The results are displayed in Figure 3.8. The measurements were performed at pH 7, in
order to compare the permeability coefficient of DOPC with the DPhPC experiments
at the same pH. The scatter plot (a) immediately tells us that norfloxacin diffuses across
the DOPC bilayer much faster − we see a shift inΔI within a time period of 9 seconds
which is comparable to the corresponding shift in ΔI in the DPhPC experiments over
a period of minutes.
This increase in permeability is reflected in the histograms (b) referencing the perme-
ability coefficient of the individual DOPC vesicles in the experiment. The average value
of the permeability coefficient (P) is determined to be 9.4 ± 0.4×10-6cm/s (N=100,
mean ± s.e). Thus the permeability of the DOPC lipid bilayer to norfloxacin is
approximately 15× the corresponding permeability of the DPhPC bilayer. This is
remarkable, considering the fact that both DPhPC and DOPC are PC lipids containing
the same headgroup. They only differ in the structure of their hydrocarbon chains, and
naïvely one would expect the solubility of norfloxacin in the hydrocarbon tails to be
similar.
3.3.2 Why is permeation through DOPC faster?
The first thing to question was whether the 340 nm UV radiation damaged the DOPC
membrane− the unsaturated double bonds (Figure 3.9) in the hydrocarbon chain could
have been sensitive to oxidation due to UV exposure. However, when experiments were
performed with DOPC vesicles at pH 5 (by Dr. S. Purushothaman, a post-doctoral
researcher in the group), norfloxacin permeability retreated to the levels observed in
the DPhPC pH 5 experiments. If UV induced oxidation was a problem, the pH 5
vesicles should also have been permeable to the drug. Since this was ruled out, we had
to look into some lipid chemistry to try and understand the difference.
Investigations into the permeability of small molecules (such as water) across different
lipid membranes have been performed by using X-ray scattering techniques to study,
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Figure 3.9 –Chemical structures of: a)DPhPC and b)DOPC lipid molecules. DPhPC
has highly branched chains, whereas DOPC has unsaturations (double bonds) in both
chains. Source: www.avantilipids.com
quantitatively, different lipid molecules. One such recent study, by Mathai and cowork-
ers [75], suggested that the water permeability of a lipid bilayer correlated well with the
area per lipid of each molecule. The average interfacial area per lipid molecule value is
a quantity used to describe the bilayer microstructure with reference to molecular pack-
ing; it is defined in reference to the average hydrocarbon thickness and the hydrocarbon
chain volume [76]. Mathai and coworkers found that the water permeability of lipid
bilayers correlated only with this Area/Lipid quantity, and not with the hydrocarbon
thickness, bending modulus nor with the compressibility modulus. They investigated
a number of different lipid types, but importantly did not investigate DPhPC.
Now, the area per lipid of DOPC was measured to be 72.4 ± 0.5 Å2 [75]. A cou-
ple of years later, the same group discovered a problem. They had decided to in-
vestigate the properties of DPhPC, and found that although its area per lipid value
was considerably larger (80.5 ± 1.5 Å2) than that of DOPC, it had a much smaller
water permeability [77]. However, molecular dynamics (MD) studies had been per-
formed previously [78] comparing the free volume distribution in the hydrophobic
3.3 Changing the lipid composition affects norfloxacin permeability 53
part of the (branched) DPhPC molecule and its straight chain counterpart DPPC (1,2-
dipalmitoyl-sn-glycero-3-phosphocholine). The simulations showed that the branched
chains present in DPhPC reduced the free volume available in the hydrophobic region
of the molecule, thus lowering the rate of diffusion of small molecules such as water
[78]. They thus concluded that when lipid molecules have branched chains, the perme-
ability to small neutral molecules is reduced.
This work led Tristram-Nagle and coworkers [77] to postulate that the biophysics of
DPhPC is substantially different to other straight chain PC lipids, and that this chain
branching is the cause of the reduced water permeability when compared with DOPC.
This explanation also accounts well for our results. As our pH dependent measure-
ments have shown, it is the neutral form of norfloxacin that translocates across the lipid
bilayer, and this small, neutral molecule shows similar permeability characteristics to
water when comparing DPhPC and DOPC lipids.
Perhaps more importantly, however, this example demonstrates precisely why it is
important to perform drug permeability studies directly on the lipid system of interest.
On the face of it, DPhPC and DOPC are both PC lipids with the same headgroup,
differing only in the structure of their hydrocarbon chains. However, that very dif-
ference in chain structure leads to a 15-fold difference in norfloxacin permeability
across membranes of the two lipid types. Real cell membranes are highly dynamic;
bacteria in particular are known to change their lipid composition depending on their
growth conditions [17]. It should also come as no surprise that they can change their
lipid composition in response to antibiotic stress; significant changes in lipid structure
were observed when comparing lipids from antibiotic resistant versus sensitive bacteria
grown under identical conditions [79]. It is imperative that future drug development
processes take this lipid dependence into account. At present, other group members are
using the optofluidic assay to investigate the drug permeability of the different types of
lipids found in E. coli membranes in an attempt to understand what lipid composition
a bacteria might adopt to reduce antibiotic accumulation.
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3.4 Tetracycline transport
In order to demonstrate that our technique is capable of studying antibiotics other than
those of the fluoroquinolone family, we used it to study the permeability of tetracycline
across DPhPC vesicle membranes. For ease of comparison with the norfloxacin mea-
surements and for physiological relevance, we again performed the measurements at
pH 7.
3.4.1 Tetracycline
Figure 3.10 – Tetracycline chemical structure. Source: www.wikipedia.org
Tetracyclines were amongst the first antibiotics to be discovered, back in the 1940s.
They are broad spectrum antibiotics that function against both Gram-positive and
Gram-negative bacteria, as well as acting against a range of other aerobic and anaer-
obic microorganisms. Their mechanism of action involves the inhibition of protein
synthesis; this is achieved by preventing the attachment of the aminoacyl-tRNA to
the ribosomal acceptor (A) site [80]. Tetracycline remains an extremely important
antibacte ial, named n the World Health Organization’s list of essential medicines
[81]. However, as with all older antibiotics, many human pathogens are now resistant
to the drug, and efforts are ongoing to better understand the molecular mechanisms of
resistance [80].
Tetr cycline has three proton-binding groups with macroscopic pKa values of approx-
imately 3.3, 7.7 and 9.7 in aqueous solutio s [82]. As with norfloxacin, a study of the
microscopic dissocia ion constants reveals that, at physiological pH values (pH 7.4),
a significa t fraction (∼7%) of the tetracycline molecules exist in an uncharged form
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[72, 82] and it is expected that this uncharged fraction contributes most to the passive
diffusion of the drug across lipid bilayers.
Tetracycline fluorescence is well known, though not all that well understood [83]. It
shows autofluorescence in the near UV at excitation wavelengths of around 360-365
nm. Its autofluorescence is weaker than that of norfloxacin, which is why we had to
use higher concentrations of the drug (8 mM). The fluorescence intensity increases
when the drug chelates divalent metal ions such as Ca2+ or Mg2+ [83], but we refrained
from using these since we wanted to determine the permeability coefficient of pure
tetracycline across the lipid bilayer. Needless to say, biologists interested in studying
the membrane transport of metal ion chelated antibiotics can use the assay to determine
how metal ion chelation affects drug transport.
Before discussing the results, a small technical point−we found it difficult to produce a
stable stock solution of tetracycline (Sigma Aldrich) in water, and therefore dissolved it
in ethanol before diluting it to 8 mM in the (aqueous) buffers used for the experiment.
To keep the properties of the two solutions being mixed constant, an equivalent amount
of ethanol was added to the vesicle solution. This helps ensure that the microfluidic
flow profiles from the two inlets are similar (i.e, the fluidic resistances are the same),
and is recommended when performing the assay with tetracycline.
3.4.2 Tetracycline transport across DPhPC bilayers
DPhPC vesicles were produced using the same protocols as before, prepared in the pH
7 phosphate buffer containing 200 mM sucrose (section 2.3.3). As with the norfloxacin-
DOPC measurements, it was noticed in preliminary experiments that tetracycline
transport was significantly faster than norfloxacin across DPhPCmembranes, and there-
fore the ‘Short’ microfluidic chip (appendix B) was employed for these measurements.
The results are shown in Figure 3.11. We looked at two viewing positions (and hence
4 different spatial locations) along the channel in our microfluidic chip. The first
viewing point was the same as that used in the DOPC measurements − the t = 0
point chosen was the earliest point post vesicle-drug mixing where the tetracycline
had diffused across the channel width. The other point in the same field of view was
7.4 mm further downstream along the channel. The second viewing position contained
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Figure 3.11 – Tetracycline transport through DPhPC vesicles at pH 7. Excitation
wavelength λex = 360 nm. a) The scatter plot shows the decrease in ΔI as the time
of vesicle exposure to the drug increases. The different time points clearly correspond
to different bands in the scatter plot, providing direct visualisation of drug uptake.
The timescales involved show that tetracycline transport through DPhPC bilayers is
significantly faster than norfloxacin transport. b) Permeability coefficient histogram
representing individual vesicle measurements. The average value of P was found to be
5.7 ± 0.1×10-6cm/s (N=271 events, mean ± s.e). Thus tetracycline permeability is an
order of magnitude higher than norfloxacin at pH 7.
detection points at 11.7 mm and 19.5 mm respectively after the t = 0 position. On
average, vesicles took 9 ± 1 seconds to the first (7.4 mm) point, 15 ± 2 seconds to the
second (11.7 mm) position and 26 ± 3 seconds ( all values are mean ± s.d) to reach the
final detection point (19.5 mm). It must be noted here that there is some redundancy in
vesicle detections, since the vesicles whose permeability was measured at the 11.7 mm
point include most of those whose permeability was measured at the 19.5 mm point,
since both positions were recorded simultaneously.
The uptake of tetracycline is beautifully visualised in the scatter plot of Figure 3.11
(a). As the distance travelled along the chip by the vesicles (and hence the time spent
exposed to the drug) increases, the internal tetracycline fluorescence increases and ΔI
decreases. The shift in ΔI from one detection point to the next is unambiguous and
clear. The histogram (b) of the permeability coefficients for the vesicle detections also
behaves as expected, and on average P = 5.7 ± 0.1×10-6cm/s (N=271 events, mean ±
s.e). This shows excellent agreement with the permeability coefficient of 6 × 10-6cm/s
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predicted [72] for the passive diffusion of tetracycline through typical biological mem-
branes (at a pH of 7.2). This prediction was based on the fact that the protonation of
the tetracycline molecule leads to approximately 7% of the molecules being uncharged
at a pH of 7.2, which itself is based on considerations of the microscopic dissociation
constants that govern the acid-base equilibria of tetracycline [72, 82]. This further
emphasises the importance of studying the pH dependent protonation states of drug
molecules and their effect on the lipid permeability of the drug. Our optofluidic assay
provides an ideal platform for performing these tests on a range of different drug and
lipid combinations.
We have thus shown that our assay is applicable to different classes of drugs. As a first
iteration, it could be used to study the permeation properties of different molecules
from the fluoroquinolone and tetracycline families, and there are many such molecules
to investigate. But perhaps more importantly, it could be used to replace existing assays
when testing the lipid permeation of new drugs; it would be most satisfying if this
technique eventually gets used in the drug discovery process.
3.5 Interaction of QuantumDots with lipid membranes
To demonstrate the versatility of our technique, we now apply it to the study of a
completely different field − the interaction of Quantum Dots with lipid membranes.
3.5.1 Quantum Dots in Biology
QuantumDots (QDs) are spherical nanocrystals with diameters in the range of 1-10 nm
[84, 85]. They are typically made of semiconductor materials, since it was noticed that
the optical and electronic properties of these materials at the nanoscale were strongly
dependent on particle diameter [85]. The strong size dependence of these properties
arises due to two major reasons [84]: firstly, the number of surface atoms in a nanocrys-
tal is a large fraction of the total. These surface atoms make a significant contribution to
the free energy, and hence control the thermodynamic properties of the material. The
number of surface atoms depends on the size of the nanocrystal, and hence changing
the diameter can have a dramatic bearing on the properties of the QD. Secondly, the
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Figure 3.12 – The emission wavelength of a CdSe Quantum Dot can be tuned in the
visible region of the spectrum by changing its diameter between 2 and 7.5 nm. Image
adapted from [85].
intrinsic properties of the interior of nanocrystals are governed by quantum size effects,
which alter the electronic properties of the material on the basis of its diameter.
One of the most important properties that is controlled by tuning the size of the QD is
the wavelength of its fluorescence emission (Figure 3.12). QDs absorb strongly in the
UV, but by changing their radius and chemical composition, their emission wavelengths
can be made to span an extremely wide range, from 400-2000 nm [85–89]. For example,
the emission of a Cadmium Selenide (CdSe) QD can be tuned between 450-650 nm
within the visible spectrum by varying the nanoparticle diameter between 2 and 7.5
nm [85].
This is of obvious interest from an imaging and labelling perspective − if one were
to use QDs with a range of radii to label specific biomolecules within a cell, one
could excite all their fluorescence using the same light source, and each species would
emit at a different wavelength. Furthermore, current techniques for the chemical
synthesis of QDs allow for excellent control over the mean particle size and particle
size distribution, enabling the production of QDs with narrow, symmetric emission
peaks and spectral properties far better than that of typical organic dye molecules [85].
These properties thus sparked a flurry of research activity aimed at making QDs viable
for use with cells. In 1998, the research groups of Alivisatos and Nie independently
achieved this feat. Alivisatos and coworkers demonstrated the use of these nanocrystals
as fluorescent markers for investigating mouse fibroblasts, using a dual emission, single
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excitation labelling experiment [90]. Nie and Chan used Zinc Sulphide coated CdSe
QDs and covalently attached these to biomolecules for ultra-sensitive biological detec-
tion [91]. They claimed that this class of fluorescent probes was “20 times as bright, 100
times as stable against photobleaching, and one-third as wide in spectral linewidth” as
compared to standard organic dyes. These ZnS-CdSe conjugates were also water soluble
and biocompatible [91]. The QDs were attached to the transporter protein transferrin
and taken up by HeLa cells via receptor-mediated endocytosis. Within the cells, the
QDs were used to recognize specific antibodies or antigens [91].
Since then, considerable research has gone into developing QDs as probes to detect, for
example, cancer markers in live tumour cells [92], for multicolour optical coding in
bioassays [93], for single particle tracking within a live cell [94] − the list is extensive.
Furthermore, these probes have been used for live animal imaging, in the hope of
developing novel imaging techniques for the early detection of cancer and other diseases
[95]. There is thus tremendous scope for this technology; it has the capacity to truly
revolutionize medical diagnostics. But, as always, there is a catch.
3.5.2 Quantum Dot Cytotoxicity
The spectral characteristics of QDs might be fantastic, but the fact remains that the
most commonly used QDs, especially those used for biological applications, have CdSe
as their core material. Cadmium is a notorious heavy metal, linked with all sorts of
undesirable health effects, from renal failure to cancer [96]. It is a Red List chemical
and its use and disposal are tightly regulated.
It is thus natural that concerns were raised regarding the use of cadmium in the core
of QDs [97–100]. Studies revealed that the main source of cytotoxicity was the release
of Cd2+ ions into cells; thus, the development of appropriate surface coatings for the
QDs that prevented the release of these ions became a major priority. Comprehensive
studies were undertaken to study the effect of various different chemical modifications
to the cytotoxicity of the QDs. It was found that a ZnS shell surrounding the CdSe
core rendered the QD biocompatible, with little cytotoxicity reported even at high
QD concentrations [98, 99].
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CdSe
ZnS
Figure 3.13 – Fluorescence micrograph showing beads labelled with a range of CdSe-
ZnS QDs emitting at 484, 508, 547, 575 and 611 nm. Image adapted from [93].
However, before the use of QDs becomes routine for animal and human imaging,
longer term studies will have to be performed to ensure that there is no build up
of cadmium in the body, and that the risk associated with the use of these QDs is
acceptable. Experiments with different coatings (such as Polyethylene glycol) are also
being undertaken, in order to reduce the accumulation of these QDs in the liver and
kidneys [101].
Interestingly, there is not much in the literature about the interaction of QDs with lipid
membranes. One report claims that 12 nm diameter CdSe QDs can form aggregates
on lipid bilayers leading to the formation of nanopores with diameters of about 2 nm
[102]. Such pores could seriously undermine the integrity of a cellular membrane.
We therefore decided to exploit the UV autofluorescence of QDs to investigate their
interaction with our DPhPC vesicle lipid bilayers, and to see whether the vesicle mem-
branes ruptured or allowed for the passive transport of these nanoparticles across the
lipid barrier.
3.5.3 Interactions with Vesicle membranes
Understanding how QDs interact with and permeate lipid bilayers is important both
for investigations into their cytotoxicity, and also for better understanding their use as
intracellular fluorescent probes. To this end, our collaborators Dr. Teresa Pellegrino
and Dr. Alberto Curcio from the Italian Institute of Technology sent us samples of
CdSe-ZnS QDs. The CdSe core had a diameter of approximately 3 nm, surrounded
by a ZnS shell. The final QDs had a mean diameter of 4.3 ± 0.5 nm, with maximum
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absorbance in the UV and an emission maximum at 561 nm (when excited at 400 nm).
Our goal was to determine whether the QDs were capable of passively diffusing across
lipid bilayers within the timescales of our permeability assay.
We performed the experiment with DPhPC lipid vesicles, prepared at pH 7. As usual,
vesicles entered from one inlet and the QDs from the other.
The diffusion of QDs across the width of the fluidic channel obviously takes a longer
amount of time compared to norfloxacin or other small molecules, so we reverted to
using a chip that was based on our initial design, where the two solutions are given
ample time to mix (∼20 seconds) before the first (t = 0) detection point. To simplify
the preliminary experiments, we used a slightly shorter version of the initial design
(appendix B ‘Medium’ chip) which allowed us to view the vesicles over a period of
approximately 100 seconds after complete mixing with the QDs.
Rather surprisingly, the UV autofluorescence of the QD sample was quite weak, and
higher concentrations of the QDs had to be used than initially expected. The stock QD
concentration was 8.49 μM, which was diluted 50 times for use in the experiments. The
SNR was therefore not ideal, but we were still able to obtain results. It is possible that
some degradation occurred during storage and/or transport, and fresh samples should
be obtained for any follow up experiments.
Figure 3.14 shows the results obtained at the longest timescale (t∼ 101 seconds) viewed.
To reiterate, the autofluorescence intensity here is due solely to the presence of QDs
in the solution. The majority of the vesicles show no shift in ΔI over the timescales
measured, which seems to suggest that the QDs do not permeate across lipid bilayers
passively. This is in line with previous reports [91] where the cellular uptake of CdSe-
ZnS QDs required functionalization with transferrin for receptor-mediated uptake. We
do notice a slight decrease in ΔI for a few (2-3) vesicles, but considering the weak SNR
in these experiments, it is likely that these are artefacts or just damaged vesicles. The
experiments at shorter timescales gave similar results as expected.
Thus it appears as though CdSe-ZnS QDs require functionalization for their cellular
uptake. We are interested in studying the effect of a Polyethylene glycol (PEG) coating,
which will reside over the ZnS shell of the QD. PEG is being used to make QDs more
biocompatible [101], and it would be interesting to check if it has any effect on the lipid
62 Chapter 3 Transport Across Pure Phospholipid Membranes
8 12 16 20
0.0
0.1
0.2
0.3
ΔI
Radius (μm)
t ~ 101 s
t = 0 s
Figure 3.14 – Scatter plot for CdSe QD permeability experiment. λex = 350 nm. The
black squares represent vesicles at the initial detection point, whereas the red circles
reference vesicles detected about 101 s later in the channel. Both populations show
almost complete overlap, indicating that no significant QD transport is observed at the
timescales measured.
permeability of these QDs. Indeed, with the permeability measurement technique in
place, the lipid permeability of a range of different QDs could in principle be tested.
3.6 Conclusions
To summarize the picture thus far, we have applied our newly developed technique, a
UV autofluorescence based permeability assay, to study a variety of different problems
in membrane transport. We have shown that it can be used, first and foremost, to quan-
tify passive antibiotic diffusion across vesicle lipid membranes, and have demonstrated
its feasibility for at least two major classes of antibiotics, the fluoroquinolones and the
tetracyclines. We further demonstrated that the assay can be used to study the effect of
lipid compositions on drug transport, and reported an order of magnitude difference
between the norfloxacin permeability of DPhPC and DOPC lipid membranes. Finally,
we showed that the same technique can be applied to transport studies of a completely
different type of particle, the Quantum Dot.
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Each of these topics − antibiotic diffusion, the effect of lipid composition on drug
permeability, the interaction of QDs with lipids − is a distinct field of study in its own
right. This is an apt demonstration of the power of technological development − one
new assay can be applied to answer a range of biologically relevant questions. And this
is just the tip of the iceberg, there are many more questions in membrane transport
that remain to be studied. We shall discuss a few current investigations in our Outlook
chapter 6 at the end of this Thesis.
For the moment however, we shall turn our attention to the study of nanopores −
specifically, the biological protein nanopores that form a vital component of all cell
membranes. These protein pores are responsible for controlling the transport of a
multitude of molecules, including drugs, across cellular membranes. The following
chapter is devoted to the application of our technique for measuring antibiotic transport
through bacterial membrane pores.
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Chapter 4
Exploring the role of Nanopores in
Membrane Transport
“Everything should be made as simple as possible, but not simpler.”
Albert Einstein (attributed)
4.1 Introduction1
Our focus until now has been on the transport of antibiotics and other particles of
interest across a pure phospholipid membrane. However, the structure of biological
membranes is far more complex, consisting of a large variety of proteins. These are
found both on the surface of the membrane (peripheral membrane proteins, or PMPs)
and inside the lipid bilayer (integral membrane proteins, or IMPs). A subset of the
IMPs contains proteins that span the length of the lipid bilayer; these transmembrane
proteins play a vital role in regulating the passage of hydrophilic molecules and ions
into cells. These transmembrane protein nanopores are in many cases the route of
choice for antibiotics attempting entry into bacterial cells. Porins are a subset of these
protein nanopores that facilitate transport across the membrane via passive diffusion.
This chapter is devoted primarily to the study of one particular porin, the E. coliOuter
1We published the work presented in this chapter in reference [103].
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Membrane Protein F (OmpF); its role in fluoroquinolone transport is investigated at
physiological pH values. Microfluidics and electrophysiology are combined to obtain
a detailed understanding of the mechanisms of fluoroquinolone uptake in E. coli, in
particular explaining previously measured pH dependencies in the uptake process. Re-
sults from the OmpF transport studies are correlated with results from the previous
chapter to provide a quantitative understanding of norfloxacin transport across both
the E. coli outer and inner membrane, in a manner not accessible to previously available
technologies.
4.1.1 The Outer Membrane of the Gram-negative Cell Wall
Figure 4.1 – Schematic of the E. coli cell envelope showing the double membrane cell
wall. The outer membrane (OM) is an asymmetric membrane with phospholipids
(PL) in its inner leaflet and lipopolysaccharides (LPS) in its outer leaflet. The OM
also contains barrel shaped protein porins, such as OmpF. The periplasm, an aqueous
compartment between the two lipid membranes, contains the peptidoglycan layer. The
inner cytoplasmic membrane (IM) is a symmetric phospholipid bilayer which also
contains various integral membrane proteins. Image taken from [104].
Gram-negative bacteria such as E. coli are characterised by the presence of a double
membrane cell wall (Figure 4.1). There are thus two hydrophobic barriers that a drug
must overcome in order to enter the cell cytoplasm, generally the location of antibi-
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otic targets. The outer membrane (OM) is separated from the inner “cytoplasmic”
membrane by a periplasmic space containing a peptidoglycan layer. In most Gram-
negatives, the OM is an asymmetric bilayer of phospholipids and lipopolysaccharides
(LPS) [105]. LPS molecules generally consist of a hydrophobic domain known as lipid
A (or “endotoxin”), a non-repeating “core” oligosaccharide and a distal polysaccharide
(or O-antigen) [106]. The strong lateral interactions between LPS molecules and their
low fluidity make the asymmetric OM much more hydrophobic than a typical phos-
pholipid bilayer [105]. In fact, such is the level of interaction that the core region of
LPS provides a strong barrier against the entry of even certain hydrophobic antibiotics;
pure phospholipid membranes are much more permeable to lipophilic compounds
[105]. Transmembrane porins found in the OM are thus the main port of entry for
most extracellular molecules entering the cell. These porins are generally water filled
channels, and the narrowest constriction in the porin determines the maximum solute
size that can pass through it [107, 108].
Before moving on to a detailed description of the OmpF porin, we must mention
here an important physical property of these bacterial membranes. There exists an
electrical potential across the cytoplasmic membrane, Δψ, which is negative inside
the cell relative to the outside. A combination of this potential and a pH gradient
(ΔpH) across the cytoplasmic membrane gives rise to a Proton Motive Force (PMF),
an electrochemical gradient of protons across the membrane that is crucial for the
metabolism of the cell [109]. Given its obvious importance, this electrical property
of the cytoplasmic membrane has been extensively studied and will not be described in
further detail here. Of more interest to our study of porins is the existence of potentials
across the OM, and it is to these that we now turn our attention.
In 1973, the discovery of a new E. coli cell constituent, the membrane-derived oligosac-
charide (MDO) was reported [110]. These oligosaccharides consist of about 8-10 glu-
cose units/mol in a highly branched structure, and are variously substituted with sn-1-
phosphoglycerol and phosphoethanolamine residues that derive from membrane phos-
pholipids (hence the name) [111]. These MDO molecules are localized to the periplas-
mic space of E. coli [112], and their synthesis plays a crucial role in the osmoregulation
of E. coli [111]. However, our interest in them stems from the fact that these molecules
are highly anionic; on average each MDO molecule contains a total net negative charge
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of 5 [111]. This negative charge anchored in the periplasm leads to the development of
Donnan potentials across the E. coli outer membrane. The magnitude of this Donnan
potential is highly dependent on the cation concentration of the medium surrounding
the bacterium; potentials in the range of about 5-100 mV have been measured as a
result of varying the external cation concentrations [113]. In the presence of typical
physiological ion concentrations, the magnitude of this potential is in the region of
20-30 mV [113].
Thus it is apparent that the OmpF porin resides in a landscape with an electrical
potential that can vary over a large range; one would expect that these electric fields
influence the transport of compounds through the porin. One would also expect
such effects to be intricately related to the charge of the compound attempting to
pass through the porin. Building on the work presented in chapter 3, we investigate
how the pH dependent charge on our model molecule, norfloxacin, influences its
transport through the OmpF porin. Combining results from both chapters will allow
us to present a physical mechanism that explains previous observations of the pH
dependence of bacterial susceptibility to fluoroquinolones.
The OmpF Porin
Figure 4.2 – The OmpF porin. Top and side views of the trimeric protein structure.
Crystal structure image adapted from the Protein Data Bank [114].
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Outer Membrane Protein F (OmpF) porins are amongst the most abundant protein
porins found in E. coli OMs; it is estimated that they are found in excess of 105 copies
per cell [105]. The OmpF porin is a symmetric trimer that consists of three copies of
a barrel-shaped, 340-residue monomeric unit [114, 115]. It forms a water filled channel
in the OM that functions as a weakly cation selective and size selective filter with an
exclusion limit of approximately 0.6 kDa for hydrophilic solutes [114, 116, 117]. It
is one of the relatively few OM proteins for which high resolution crystal structures
exist [114, 115], enabling an in depth study of its solute selective properties. In fact,
OmpF was amongst the first membrane proteins to be studied by X-ray crystallography
[115, 118].
Unusually for a membrane protein, the OmpF sequence is predominantly polar; there
are no long hydrophobic segments such as those found in other transmembrane pro-
teins [115]. However, the external surface of the barrel contains lipophilic side chains
that help the protein straddle the lipid membrane [116]. Its secondary structure consists
almost entirely of β-sheets [115, 119]. The β-strands are tilted by between 30-60o in
relation to the barrel axis, and this tilt leads to an increase in the pore diameter [116].
The crystal structure showed that the ‘eyelet’ of the channel, i.e., its constriction
site, was 1.1 nm by 0.7 nm [115, 116]; it is this constriction that determines the
size selectivity of the channel. At these length scales, the diffusion of solutes is also
determined by the amino acid residues lining the internal channel wall, and indeed a
study of the residues explains the slight cation-selectivity of the OmpF porin [116].
The role of porins in Fluoroquinolone Transport
In chapter 3, we saw that the fluoroquinolone antibiotic norfloxacin easily diffuses
across a pure phospholipid membrane when in its neutral form; when it is protonated
(positively charged) at acidic pH values, this diffusion is much slower [13].
However, the diffusion of even the neutral, lipophilic version of norfloxacin through
the OM is hindered by the presence of LPS. Thus porin mediated diffusion becomes
vital for the entry of these antibiotics into the bacterial cell. Inevitably, one of the pri-
mary mechanisms of fluoroquinolone resistance in bacteria is thus the downregulation
of these porins, which dramatically decreases the accumulation of these antibiotics in
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the cell [23, 105, 120]. A reduction in OmpF expression has been directly associated
with decreased fluoroquinolone uptake [23, 121–123]. Moreover, antibiotic therapy
has been associated with a shift in porin expression in vivo from OmpF to the narrow
OmpC family of porins, whose smaller channel constriction reduces the passage of
antibiotics through the OM [23].
However, a response to antibiotics is not the only mechanism by which porin medi-
ated transport is regulated; the environment around the bacterium also plays a crucial
role. The expression of the OmpF and OmpC porins in E. coli is governed by the
OmpR/EnvZ two component system, and is affected by both the osmolarity and
the pH of the surrounding medium [124]. In addition, the nutrients present in the
surroundings also influence porin expression [124]. However, OmpF and OmpC
proteins were also expressed in experiments with EnvZmutants at a low pH, suggesting
that alternative porin regulation pathways might be used in this regime [124]. Though
the pH dependence of porin expression still needs further clarification, it has been
reported that high osmotic pressure, high temperature and acidification of the medium
leads to a switch in porin expression from OmpF to OmpC [125] which should lead to
a decrease in antibiotic uptake, as mentioned above.
In fact, changes in bacterial susceptibility to fluoroquinolones due to changes in pH
have been reported previously. An increase in external pH from acidic (5.6) to basic
(8.3) was shown to correspond to a reduction in the minimum inhibitory concentration
(MIC) of norfloxacin [126]. It was proposed that this pH mediated change in fluoro-
quinolone susceptibility is related to changes in the uptake of fluoroquinolones due to
alterations of the electric charge on the antibiotic molecule [72, 127]; norfloxacin, as we
know, is positively charged at pH 5 and neutral (zwitterionic or uncharged) at pH 7.
It thus seems reasonable to assume that the fluoroquinolone susceptibility of bacteria
in response to pH changes is a complicated process, involving both changes in porin
expression and changes in drug transport properties, both through porins in the OM
as well as through the phospholipid inner membrane.
One might ask whether the study of pH dependent antibiotic transport is worth-
while. However, it should be obvious that an ability to survive in varying habitats
is fundamental to the ubiquity of bacteria. In particular, they have developed various
mechanisms for coping with changes in external pH [109]. To colonize the human
4.1 Introduction 71
gastrointestinal (GI) tract, for example, E. coli must be capable of surviving in a pH
range of 4.5-9 [128, 129]. For a drug to be effective in all regions of the GI tract, an
understanding of the pH dependence of antibiotic uptake is thus imperative. Our mea-
surements were performed within this range, at pH 5 and pH 7, in order to elucidate
the effect of the pH dependent norfloxacin charge state on its transport through OmpF.
4.1.2 Traditional Experimental Techniques used in Porin transport
The study of the diffusion of solutes through porins has previously been conducted us-
ing one of two general techniques. The first involves the use of multilamellar liposomes
in ‘liposome swelling assays’. These involve reconstituting porins into multilayered
proteoliposomes and measuring solute diffusion rates in relation to another solute, gen-
erally a fully permeable sugar like arabinose [23, 116]. The second popular technique
involves the reconstitution of porins into planar lipid bilayers, and studying blockages
in the ionic current passing through the porin in the presence of an antibiotic/solute
molecule [105, 130]. Such electrophysiology measurements enable measurements on
single porins, and can boast single molecule resolution. A less common approach
involves porin studies in intact cells, where the influx of a hydrophilic solute is coupled
with another process such as hydrolysis of the solute in the cytoplasm; the hydrolysis
can be monitored using optical density measurements [116, 131]. However, since some
form of solute hydrolysis is required, this naturally limits the different types of solute
that can be used in such an assay [132]. The other problem inherent in the technique
is a lack of precise control over the influx pathways, since any number of different
transport pathways could be used. We shall therefore not discuss this further. All
three techniques thus have their strengths and weaknesses, and their relative merits
are fiercely debated [116]. We shall briefly introduce liposome swelling assays and
electrophysiology techniques, before we move on to discuss our own novel technique
for porin studies and the results we obtained.
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Liposome Swelling Assays
Liposome swelling assays (Figure 4.3) involve the reconstitution of pure porin prepa-
rations into multilamellar liposomes [108, 131, 132]. The liposomes are prepared in
the presence of a polymer (generally a type of sugar); these are mixed in an isotonic
polymer-free solution containing the solute of interest and the optical density (OD)
is measured. If the solute is impermeable, the OD does not change. However, if the
solute is permeable, this creates an osmotic gradient which leads to the influx of water,
thus swelling the liposome (hence the name, swelling assay). This will eventually lead
to the bursting of the liposome and a corresponding decrease in OD [23].
a) Impermeable - no influx b) Permeable - water influx c) Liposome bursting
Sugars Antibiotics Porins
Figure 4.3 – Liposome swelling assays. a) Multilamellar liposomes are prepared
encapsulating a polymer (sugar). These are mixed with an osmotically balanced
polymer free solution containing the molecule (antibiotic) of interest. If the molecule
is impermeable, the OD stays the same. b) If the molecule is permeable, this creates an
osmotic gradient and water will swell the liposome, changing the OD. c) Eventually,
this leads to the bursting of the liposome and the release of the polymer, which reduces
the OD. The permeation rate is inferred by studying the decrease in OD. Image taken
from [23].
This technique has been used to compare the diffusion of solutes of various sizes through
porins. The channel size predicted by this method (based on solute exclusion) was
remarkably accurate when compared with the known porin crystal structures [116].
The technique measures the flux of the solute by comparing its diffusion against a per-
meable sugar (generally arabinose); thus only relative rates of diffusion can be measured
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[133, 134]. However, there are other, more serious, problems. The liposomes respond
non-specifically to any solute, and hence one has to take great care in ensuring that any
swelling observed is due to the solute of interest. Furthermore, when dextrans are used
in liposome formation, it leads to the accumulation of cations inside the liposomes
due to the build up of Donnan potentials. Thus the isoosmotic concentration for
solutions of test solutes cannot be found by simply measuring the osmotic activity
of the dextran [133]. The pioneer of this technique, the ‘porinologist’ Nikaido, has
himself warned of the dangers of modifying any of the protocols involved; the pos-
sibility of misinterpreting results or observing artefacts is high [133]. Finally, since
here porin incorporation is uncontrolled, one must always estimate the flux per porin;
single channel resolution is not possible. Thus there are intrinsic problems inherent in
the technique, and alternative technologies for porin studies were sought.
Single Channel Electrophysiology
Single channel electrophysiology has become the method of choice in the study of
porins [23, 105, 130], since it provides single porin resolution and enables the study
of molecular interactions with the porin. The experimental setup generally involves
a teflon membrane with an aperture (normally 60-80 μm in diameter) separating two
symmetrical reservoirs (cuvettes). Electrolyte solutions are present in both chambers
and an ionic current is driven across the aperture via the application of a transmem-
brane voltage. An artificial lipid bilayer is painted across the aperture and a stock
solution of porin added to one of the chambers; insertion of the porin across the
lipid bilayer leads to a well-characterized jump in the ionic current. Using appropriate
porin concentrations, and with appropriate dilution protocols, single channel recon-
stitution can be achieved. The electrical properties of the membrane and porin can
then be characterized. The addition of sugars or antibiotics to one chamber and their
subsequent diffusion through the porin leads to blockages in the ionic current; high
resolution analysis of these ionic current fluctuations leads to a detailed understanding
of the transport of single solute molecules through the porin, making this a powerful
technique [23].
However, for all its success, electrophysiology has its own problems. For example,
when used to measure channel size in some mutants of the E. coli OmpF porin, elec-
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Figure 4.4 – Single channel electrophysiology. a) Experimental apparatus (‘cuvette’)
used to create the artificial membrane. The two chambers are filled with an electrolyte
and ionic currents are driven across the membrane by applying an electric potential.
b) Schematic view of a single porin in the lipid bilayer. c) The ionic current across
the membrane increases in a stepwise manner on the incorporation of a porin in the
bilayer. d) When antibiotics are added, they permeate inside the channel and block the
ionic current. e) A single antibiotic blocking event takes about 1 ms. Data obtained
using 1 M KCl, a transmembrane potential of 50 mV and 5 mM ampicillin. Image taken
from [23].
4.2 Experimental Techniques and Materials 75
trophysiology showed a decrease in size whereas swelling assays and crystallography
both showed the opposite [116]. Another issue with electrophysiology is that it cannot
differentiate between translocation and binding events, since molecule transport is not
directly observed [135]. Finally, the technique necessarily involves the application of
transmembrane voltages; although important in the study of the voltage dependence of
porin transport, in some cases these voltages have been suspected of producing artefacts
in the results [130]. Thus, although single channel electrophysiology is widely used,
there are problems associated with it that need to be addressed.
There is therefore a need to find alternative techniques capable of studying solute
transport through porins, which could circumvent the flaws inherent in traditional
methods. We therefore decided to modify our optofluidic assay to make it viable for
the study of porin embedded proteoliposomes.
4.2 Experimental Techniques and Materials
4.2.1 Optofluidic Permeability Assay
The optofluidic permeability assay builds on the work described in the previous chap-
ters studying the permeability coefficient of norfloxacin across lipid membranes. It
was designed to explore properties of porin mediated transport not accessible to elec-
trophysiology and other traditional techniques. It enables the study of drug transport
through porins without the application of a transmembrane voltage. The optofluidics
assay also presents a direct visualisation of norfloxacin uptake across a proteoliposome
membrane and enables the measurement of contributions to diffusion from pure lipids
and through porins, which cannot be done in a quantitative manner using the older
liposome swelling assays [23, 108, 132].
As described in Figure 4.5, the optofluidic permeability assay involves the ‘Short’ T
junction microfluidic chip where the vesicles (liposomes/proteoliposomes) and the
drug molecules are mixed in a channel (via the application of suction at the outlet). The
T junction geometry of the chip leads to an equal mixing of vesicle and drug solutions.
The inlet norfloxacin concentration is 2 mM and hence the vesicles are exposed to a
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Figure 4.5 – Schematic of the OmpF optofluidic permeability assay. Control
experiments (no porin) are represented in (a) and proteoliposome experiments
(containing OmpF) in (b). Vesicles (liposomes/proteoliposomes) are mixed with
norfloxacin in a T junction microfluidic chip by applying suction at the outlet
reservoir with a syringe pump; norfloxacin autofluorescence is stimulated with a UV
epifluorescence microscope. The vesicles are detected at an initial time ti immediately
post mixing and at a later time tf, a distance 7.4 mm further downstream. Vesicles
took, on average, about 7.5 s to travel the intervening distance. Both time points are
observed in the same field of view. Detection of the autofluorescence intensities within
the vesicles at both points enables the calculation of the drug permeability coefficient
for each vesicle. Published in [103].
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final norfloxacin concentration of 1 mM. The vesicles are imaged immediately post
mixing with the norfloxacin and at a distance 7.4 mm further along the channel, both
points being observed in the same field of view.
The work described in chapter 3 involved the use of our custom built UV epifluores-
cence microscope with an EMCCD camera, a setup that was tailored for this experi-
ment. However, to demonstrate the versatility of the technique, we performed all the
OmpF optofluidics experiments described in this chapter on a commercial Olympus
IX73 microscope, using a DAPI filter set (Chroma) and an arc lamp (Prior Lumen
200). A 60× air objective was used (Olympus LUCPlanFLN, NA 0.70). Images
were recorded using a scientific CMOS camera (optiMOS, QImaging) which enabled
recording at 100 fps (10 ms exposure, bin 4).
4.2.2 Vesicle formation and OmpF incubation
GUVs of DPhPC lipids (Avanti Polar Lipids) were prepared via electroformation using
a Nanion Vesicle Prep Pro (Nanion Technologies GmbH, Germany) setup as described
previously (section 2.3.3). The GUVs were prepared in 200 mM sucrose with 5 mM
phosphate buffer (pH 7) or 5 mM acetic acid (pH 5).
The OmpF incubation followed previously established protocols [136]. Purified stock
OmpF (5.5 mg/ml) was provided (courtesy the Winterhalter laboratory, Jacobs Uni-
versity Bremen) in a detergent, a 1% solution of n-Octylpolyoxyethylene (octyl-POE,
Bachem) prepared in Millipore water. The stock OmpF was diluted 1:1 in the same
detergent and vortexed; 1 μl of this freshly diluted OmpF solution was added to 199 μl
of the vesicle stock solution and incubated at room temperature for an hour. Biobeads®
SM-2 (Bio-Rad) were added to remove the detergent and the mixture was incubated at
room temperature for 45-60 minutes followed by storage at 4 °C overnight. The next
day, the OmpF embedded proteoliposome solution was separated from the Biobeads
with a pipette and the sample used directly in experiments. For the control (liposome)
experiments, 1 μl of 1% octyl-POE (instead of the OmpF solution) was added to 199 μl
of the vesicles; the rest of the incubation protocol remained unchanged.
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4.2.3 OmpF insertions counted using ionic current sensing
In order to calculate the norfloxacin flux per OmpF porin in the optofluidics assay, we
needed a calibration measurement that would allow us to estimate the number of porins
embedded in each proteoliposome. This measurement was done by our collaborators
in Jacobs University Bremen, Germany (Winterhalter group). Briefly, proteoliposomes
were prepared in a similar manner as for the optofluidics assay; however, the OmpF
concentrations used were a factor of 500×, 250× and 100× smaller, so that single
insertions could be measured. Higher porin concentrations could not be used because
the resultant patches were unstable. A planar lipid bilayer containing the proteins
was formed by pipetting 5 µl of the proteoliposomes into a similar amount of the
electrolyte solution (200 mM KCl, 5 mM acetic acid for pH 5 or 5 mM phosphate for
pH 7). The resulting solution was placed on a microstructured glass chip (grounded
side) containing an aperture approximately 1 µm in diameter. The vesicles burst once
they touch the glass surface of the chip thus forming a planar lipid bilayer; additional
suction was applied to patch the proteoliposomes across the aperture. Ionic current
measurements were performed using an Axopatch 200B amplifier in voltage clamp
mode. An on board low pass Bessel filter was used at 10 kHz; the sampling frequency
was 50 kHz.
From the calibration curve (Figure 4.6), we see that the number of porins per patch
increases linearly with porin concentration. The large errors in the measurements
indicate the variability in OmpF insertion efficiency in different vesicles. This can
be due to various reasons − all electroformation protocols lead to a small population
of multilamellar vesicles [36], and in these the porins will not be able to insert. Fur-
thermore, OmpF mixing with vesicles is not controlled in our protocol, and hence
is not expected to be uniform. However, for the purposes of estimating the flux per
porin, this calibration measurement is sufficient; the large error in insertion efficiency
is reflected in the spread in permeability coefficients obtained in the experiments.
Extrapolating from the calibration curve, we obtained a value of∼1,800 porins per μm2
for the proteoliposomes used in the optofluidics assay (for comparison, it is estimated
that general diffusion porins are present at >105 copies per bacterial cell [105], which
translates into an approximately 6-7× higher [porin]:[lipid surface area] ratio than in
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Figure 4.6 – OmpF insertion efficiency calibration. A range of OmpF concentrations
were measured in proteoliposomes in a Port-a-Patch setup. The number of OmpF
porins per membrane patch (d = 1 μm) were counted and used to plot a calibration
curve. The OmpF concentrations displayed are normalised with respect to the
concentrations used in the optofluidics assay. Within error, we observe a linear increase
in the number of porins measured per patch. Extrapolating to the concentrations used
in the optofluidics assay, we estimate 1750 ± 114 porins per μm2 in the vesicles at pH
5 and 1871 ± 137 porins per μm2 at pH 7 (values are mean ± s.e). For each OmpF
concentration, four batches of vesicles were prepared at both pH 5 and pH 7. The
number of proteoliposome patches measured for each OmpF concentration (at each
pH) was, in order of increasing OmpF concentration, N = 17, N = 6 and N = 11.
Measurements performed by Dr. Harsha Bajaj. Published in [103].
our experiment). The vesicle radius is measured in the optofluidic assay; one can thus
calculate the surface area of each vesicle and use the calibration measurement to estimate
the number of porins per vesicle. The permeability coefficient of the vesicle contains
information about the total flux of drug molecules into the vesicle, and hence a rough
estimate of the flux per porin can be calculated.
4.2.4 Flux calculations
The flux (J ) through a proteoliposome can be calculated from its permeability coeffi-
cient (P) as follows:
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P = −
(
R
3t
)
× ln(∆I(t)−∆I(0) + 1) (4.1)
J = 4piR2×P×(∆I(t)−∆I(0) + 1)×cout (4.2)
where cout is 1 mM. The main contribution to J is the flux through the OmpF porins
in the proteoliposomes. There is a small contribution that arises due to norfloxacin
diffusion through the pure lipid bilayer. This can be quantified using known values of
the permeability coefficient of norfloxacin across DPhPC vesicle membranes, reported
in chapter 3. The control measurements show that in the absence of porins, ∆I(t)
∼ ∆I(0) on the timescales measured. Therefore, the (maximum) contribution of the
diffusion through lipids, Jlipids, to the total flux measured is given by:
Jlipids = 4piR
2×Plipids×cout (4.3)
where cout is 1 mM, as usual. From chapter 3, we know that Plipids = 0.006 μm/s at pH
7 and Plipids ∼ 0.001 μm/s at pH 5.
The actual flux through all the porins in a proteoliposome, Jporin, is thus:
Jporin = J − Jlipids (4.4)
Dividing Jporin by the number of porins in the proteoliposome gives us the flux per
porin for that proteoliposome.
4.2.5 Data Analysis
In the data analysis of the optofluidic assay, four filters were applied to separate genuine
vesicle detection events from lipid aggregates.
• The circularity criterion (as defined in equation (2.16)) was 0.7.
• Only those vesicles with radii between 20 and 45 pixels (i.e. 8.8-19.7 μm) were
chosen for analysis; vesicles with radii below 20 pixels were difficult to distinguish
4.3 Results 81
from lipid aggregates, and were hence discarded. Since the microfluidic channel
width is 40 μm, vesicles with radii greater than 20 μm were subject to shear by
the channel walls, which can affect drug uptake. Therefore these events were
discarded as well.
• Vesicles with velocities only between 0.4-1.5 mm/s were chosen for analysis.
Events with velocities above 1.5 mm/s were generally false positives; events below
0.4 mm/s were either false positives or cases where vesicles were moving along
the channel walls and were hence subject to shear.
• Finally, it was observed that ∆I values below 0.05 were associated with lipid ag-
gregates and false positives. Therefore all events with ∆I < 0.05 were discarded.
The main purpose of the selection criteria is to speed up the analysis process. However,
as mentioned earlier, the frames corresponding to vesicle events are saved separately
during image analysis in MATLAB, and hence each point in the scatter plots can be
checked visually as well if desired.
4.3 Results
4.3.1 Optofluidic assay reveals norfloxacin uptake through OmpF
The results of the optofluidic permeability assay are illustrated in Figure 4.7 − results
from other proteoliposome experiments are presented in Figure 4.8. As before, the
graphs show a normalised intensity difference (∆I = {(Iout – Iin)/Iout}) between the
background autofluorescence intensity (Iout) and the autofluorescence intensity inside
the vesicle (Iin), versus vesicle radius (R). Each point represents a single vesicle mea-
surement. The grey squares reference vesicles at the initial viewpoint immediately
post mixing with the norfloxacin (which for convenience we set to t = 0). The green
triangles (pH 5) and red circles (pH 7) reference vesicles once they have travelled along
the channel to the next detection position.
The norfloxacin concentration present in the channel after diffusive mixing is about 1
mM; at t = 0, there is no norfloxacin inside the vesicles, whereas outside the vesicles
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Figure 4.7 – Optofluidic permeability assay shows the rapid uptake of norfloxacin
in OmpF embedded proteoliposomes. Comparison of the uptake measurement in
liposomes and proteoliposomes at pH 5 (a, b) and pH 7 (c, d). Each point references
an uptake measurement at the single vesicle level, the grey points being t = 0 and the
green (pH 5) and red (pH 7) being the final detection point t = tf. On average it took
vesicles about 7.5 s to move from the initial to the final detection point. In the absence
of porins (a, c), there is no shift in ΔI values observed at the later time at either pH.
The presence of porins (b, d) leads to a marked downward shift in ΔI for the majority
of proteoliposomes at the later detection point, both at pH 5 and pH 7. The downward
shift in ΔI corresponds to an increase in the norfloxacin autofluorescence intensity
within the proteoliposome (Iin), and is thus a direct measure of drug uptake. Published
in [103].
the concentration is 1 mM. At both pH 5 and pH 7, the presence of the OmpF causes
a marked downward shift in the ∆I values of vesicles at the final viewpoint as opposed
to the control experiments, indicating rapid accumulation of the drug inside the pro-
teoliposomes. In the absence of the porins, a similar degree of drug accumulation is
only observed over much longer timescales (as presented in chapter 3), indicating that
OmpF porins significantly enhance the permeability of the membranes to norfloxacin.
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This can be seen in the repeat porin measurements presented in Figure 4.8 as well.
Figure 4.8 – Norfloxacin uptake measurements of OmpF-embedded proteoliposomes
in the optofluidic assay. a) and b) show results from two individual experiments
at pH 5 with different batches of vesicles. Likewise, c) and d) show the results of
two experiments at pH 7, conducted with different vesicle batches. The same porin
concentration was used for all the experiments. Differences in the nature of the spread
can be attributed to variations in the vesicle batch quality and porin insertion efficiency.
However, in all plots enhanced uptake is observed for a significant proportion of the
proteoliposomes. Published in [103].
Histograms representing the combined results of 3 separate proteoliposome experi-
ments at each pH are presented in Figure 4.9.
The presence of the porins leads to similar permeability coefficients at both pH 5 and
pH 7, suggesting that the charge of the molecule does not play a significant role in
influencing its transport through the porin in the absence of a transmembrane poten-
tial. The spread in the permeability coefficient histograms is caused by the inevitable
variability of OmpF insertion into individual vesicles prepared for the optofluidics
experiments. This can be seen in the scatter plots Figure 4.7 and Figure 4.8 as well
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Figure 4.9 – The histograms are a record of permeability coefficients (P) measured for
individual porin-embedded proteoliposomes, and summarize the data from 3 separate
experiments at each pH. Histograms from the control measurements with liposomes
(no porins) are overlaid to show the shift in P due to the presence of porins in the
membrane. Total liposomes/proteoliposomes detected were N = 268 (pH 5, with
porins), N = 74 (pH 5, no porins), N = 420 (pH 7, with porins) and N = 74 (pH 7,
no porins). Published in [103].
− it is clear that, at both pH conditions, a handful of vesicles do not show significant
transport. It is known, however, that electroformation produces some multilamellar
vesicles [36], and in these the porins cannot insert across the membranes; this would
account for the few negative observations.
Norfloxacin Flux Calculation in the Proteoliposomes
Our Port-a-Patch calibration curve (Figure 4.6) yielded an estimate of ∼1,800 porins
per μm2 for the proteoliposomes used in the microfluidics assay. Since we measure
the vesicle radius in the optofluidic assay, it is straightforward to calculate the surface
area of each vesicle and use the Port-a-Patch calibration measurement to estimate the
number of porins per vesicle. Using the equations in section 4.2.4, an average over all
events (neglecting the contribution of flux through pure lipids) gives a flux value of 10
± 8 norfloxacin molecules/s per porin at pH 7 (N = 420) and 15 ± 10 molecules/s
(mean ± s.d) per porin at pH 5 (N = 268). Subtracting the contribution due to the
diffusion through pure lipids leaves the flux values unchanged, as expected considering
the timescales over which the measurements were performed [13, 103].
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4.3.2 Single OmpF Channel Electrophysiology measurements
The measurements presented in this subsection were performed by our collaborators in
Bremen (Harsha Bajaj, Winterhalter group). We shall therefore not go into great detail,
and will only briefly summarize the technique and results obtained, since these results
are relevant to the model for norfloxacin accumulation in E. coli.
This experiment involves the study of single OmpF channels reconstituted in a planar
lipid bilayer using the technique pioneered by Montal and Mueller [34]. Traditionally,
a lipid bilayer is formed across an aperture (diameter ∼ 30-60 μm) in a teflon film
that separates two reservoirs in a cuvette. The reservoirs are filled with an electrolyte
solution and a potential difference is applied across the lipid membrane via electrodes
in the reservoirs. Porins are reconstituted in the lipid bilayer and their conductance
properties studied by measuring the ionic current flowing through the membrane.
The addition of antibiotics leads to blockages in the ionic current, since the antibiotic
molecules displace ions flowing through the porin. By studying properties such as the
residence time of the antibiotic in the channel and the frequency of blockage events,
it is possible to infer kinetic association and dissociation rates that characterize the
interaction of the antibiotic with the porin [137]. Using these measured properties, it is
possible to calculate the antibiotic flux through the porin based on a suitable transport
model [138–140].
Measurements were performed using transmembrane voltages of 25 mV and 50 mV,
and a norfloxacin concentration difference of 250 μM between the two reservoirs of the
cuvette. In both instances, it was found that the residence time of norfloxacin in the
channel at pH 5 was an order of magnitude lower than the corresponding residence
time at pH 7. This immediately suggests that the positive charge on the drug molecule
at pH 5 leads to it being driven through the channel in the presence of a transmembrane
voltage. At pH 7, the overall charge on the norfloxacin molecule is neutral and therefore
the voltage is less important; free diffusion is the primary driving agent for transport
through the porin. However, there might still be some small voltage dependent effects
since the molecule is zwitterionic at pH 7 – this requires further investigation.
The above interpretation seems validated by the flux values obtained. At an applied
transmembrane voltage of−25 mV, the norfloxacin flux value (per porin) was found to
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be ∼ 1 molecule/s at pH 7 and ∼ 2 molecules/s at pH 5. An increase in the transmem-
brane voltage to −50 mV results in an increase in the flux at pH 5 to 5 molecules/s;
the flux at pH 7 remains unchanged. Note that the flux was calculated using Δc = 1
mM, to compare with the optofluidic permeability assay results described previously.
This is justified since it was observed that the number of antibiotic events in the ionic
current recordings increased linearly with an increasing concentration of the antibiotic,
and hence the rate constants measured with a concentration difference of 250 μM were
equally applicable at a concentration difference of 1 mM.
4.4 Discussion
In this study, we used an optofluidic permeability assay alongside traditional porin
electrophysiology to explore the pH and voltage dependence of norfloxacin transport
through OmpF porins. The optofluidic assay directly proves that the uptake of nor-
floxacin in the proteoliposomes is much faster due to the OmpF porins embedded in
the proteoliposome membranes, as compared to pure lipid membranes (no porins).
An interesting pattern emerges: in the absence of any transmembrane potential, the
optofluidics assay shows that the flux per porin is essentially the same (within error) at
both pH 5 and pH 7. However, as the transmembrane voltage is increased (electrophys-
iology), the flux at pH 5 starts to increase over the flux at pH 7. At a transmembrane
voltage close to typical physiological OM Donnan potentials [113] of −25 mV, the
flux at pH 5 is twice as large compared to the observation at pH 7. On increasing the
transmembrane voltage to−50 mV, the flux at pH 5 increases to five times that at pH 7.
This confirms that the positive charge on norfloxacin at pH 5 contributes significantly
to its transport across porins in the presence of transmembrane voltages.
It has been reported that a change in the pH from acidic to basic reduced the minimum
inhibitory concentration (MIC) of norfloxacin [126]; furthermore, the cytoplasmic
accumulation of norfloxacin peaks at a pH of 7.5 [72]. This agrees well with the data
obtained in our study. As mentioned above, our experiments suggest that norfloxacin
will accumulate in the periplasm of an E. coli bacterium at a 2× faster rate at pH 5 than
at pH 7 under typical physiological conditions, due to porin mediated transport across
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the OM. However, the drug molecules now encounter the phospholipid inner mem-
brane (IM). Our previous results [13] showed that the direct diffusion of norfloxacin
through a pure vesicle lipid bilayer is more effective (by a factor of approximately 6×)
at pH 7 than at pH 5. It is also known that the periplasmic pH is the same as the
external pH [128]. Considering the relative rates of norfloxacin transport across the
twomembranes at pH 5 and pH 7 thus explains the greater cytoplasmic accumulation at
the higher pH. This suggests that diffusion through the inner membrane might present
the rate limiting step. However, the permeation of Mg2+ chelated antibiotics could
further influence the uptake process through both the OM and IM. It should also
be remembered that medium acidification leads to the preferential expression of the
narrower OmpC porins over OmpF [125], which would further reduce norfloxacin
accumulation at acidic pH values.
Our analysis of norfloxacin transport through porins and lipids has thus clarified some
of the mechanisms by which drug transport is affected under changing external condi-
tions. The optofluidics assay also presents a direct visualisation of norfloxacin uptake
across a proteoliposome membrane in a label-free assay not previously possible, and
unambiguously confirms the importance of these porins in facilitating the transport
of fluoroquinolone antibiotics across lipid barriers. In addition, our optofluidic tech-
nique enables the measurement of contributions to diffusion from pure lipids [13] and
through porins, which cannot be done in a quantitative manner using the established
liposome swelling assays [23, 132]. Furthermore, our microfluidic based approach has
the potential to explore a wide range of porins. Proteoliposomes could be devised
containing a combination of passive diffusion porins and active transporters, to study
competition between these processes. New vesicle preparation techniques [141] have
shown considerable promise for integration into lab-on-a-chip devices, which should
translate into better control over porin insertions and proteoliposome modification. A
combination of traditional and advanced single vesicle techniques can thus be used to
investigate a variety of drug transport phenomena, an urgent need in medicine today.
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4.5 Conclusions
Our investigations into norfloxacin transport across phospholipid membranes and the
OmpF porin have thus yielded a more detailed, quantitative understanding of its passive
transport rates across bacterial membranes. We have experimentally demonstrated that
the charge state of the drug molecule (and by association, the pH of the surrounding
environment) dramatically influences its transport across lipid membranes; we have
thus validated theoretical predictions [72] on this topic. The technology developed
is capable of studying these processes in proteoliposomes of varying lipid and porin
constitutions, and indeed the next steps in this direction would involve the use of lipids
that more closely resemble those found in bacterial cells (already under investigation)
and combinations of import and eﬄux pathways to study the effect of these competitive
processes.
A lack of control over protein incorporation in the vesicles is the obvious roadblock
to such further investigations. However, microfluidic vesicle preparation techniques
[141, 142] have recently been demonstrated that should enable much better control of
protein insertion, by incorporating all the mixing steps into lab-on-a-chip devices. This
is the great advantage of microfluidic techniques − one can replace traditional bulk
pipetting procedures with finely controlled mixing on the single vesicle level. Clever
design of the chip geometry could suitably enhance protein insertion efficiency, and
step by step, a better approximation of a true bacterial membrane could be developed.
Further experimental capabilities of this technique will be discussed in chapter 6. Before
that, however, we shall delve next into a discussion on bacterial signalling, an ongoing
investigation that has great potential with regards to understanding the antibiotic stress
response in bacteria.
Chapter 5
Indole signalling in Escherichia coli
“Are we [humans] in charge, or are we simply hosts for bacteria? It all
depends on your outlook.”
Neil deGrasse Tyson (Space Chronicles: Facing the Ultimate Frontier)
5.1 Introduction1
This Thesis has thus far been devoted to studying the passive transport of antibiotics
across artificial cell membranes, and to the development of new techniques to measure
the same. However, such transport studies can be applied to other small molecules
as well. Cellular signalling, in both prokaryotes and eukaryotes, is governed by the
transport of small, drug-like molecules and ions across cell membranes [144–147].
In bacteria, the indole molecule has generated interest as an inter-species and inter-
kingdom signal [144, 145, 148]. By tracking indole molecules using their UV autoflu-
orescence, previous work in our laboratory showed that indole can passively diffuse
across E. coli lipid membranes [149].
The rate at which indole diffuses out through the cell membrane is critical − when
produced rapidly within the cell, its lipophilicity means that indole accumulates in the
membrane before diffusing into the surrounding medium. This leads to transiently
1We published the work presented in this chapter in reference [143].
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high concentrations of cell associated indole, which we have termed the indole ‘pulse’
[143]. This was a hitherto unknown aspect of indole signalling, that governs the entry
of E. coli cells into their stationary growth phase.
This project was carried out in collaboration with the group of Dr. David Summers
(Dept. of Genetics, Cambridge). The work described in this chapter to elucidate the
indole pulse is a small part of the much larger story of indole signalling in E. coli, but it
is of particular interest because it stands as the culmination of many years of both pure
biological and biophysical investigations performed in our laboratory.
5.1.1 Indole
H
N
Figure 5.1 – The indole molecule. Source: www.wikipedia.org
Indole (Figure 5.1) is a molecule that is ubiquitous in the bacterial community − it
is known to be produced by at least 85 different species of bacteria, spanning both
Gram-positive and Gram-negative species [144]. It is produced by the degradation
of the amino acid tryptophan. In the presence of the enzyme tryptophanase (tnaA),
tryptophan is converted into indole, pyruvate and ammonia [150].
Indole is known to be a key bacterial signalling molecule − it is involved in regulating
plasmid stability [151], acid resistance [152] and the expression of eﬄux pumps in E.
coli [153]. It plays a role in the modulation of biofilms [154], and has been linked to
a number of stress response mechanisms in bacteria, including an antibiotic response
[155]. Perhaps even more interestingly, indole is found in considerable quantities (0.5-
1.0 mM) in the human gut, a consequence of the trillions of bacteria present there
[156] − it has been found to regulate gene expression in human enterocyte cells, and
is believed to play an important role in the response of epithelial cells in the gut to
pathogens [145]. Recent work has also shown that indole can affect the hormone
secretion of enteroendocrine cells in the gut, with significant effects on the host’s
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metabolism [148]. All these signalling mechanisms are active at indole concentrations
typically ranging between 0.5-1.0 mM.
An investigation into the electrical properties of indole revealed that it also behaves as
a proton ionophore, capable of shuttling protons across cellular membranes [157, 158].
At high enough concentrations (3-5 mM), it was shown that this ionophore activity
of indole was capable of blocking E. coli cell division by depolarising the membrane
potential [157]. However, such high concentrations of indole are not typically found in
bacterial culture supernatants [159], and hence the biological relevance of these effects
was open to question.
However, it was also known that tryptophanase expression is strongly up-regulated
by the stationary phase sigma factor RpoS [160], which leads to an increase in indole
production as cells approach stationary phase [151]. We postulated that, if the indole
production rate in a cell exceeded the rate at which indole left the cell, there could tran-
siently exist a state in which the cell experienced high concentrations of indole. This
pulse could, we believed, lead to indole concentrations that were capable of shutting
down the cell division machinery via the ionophore effect.
In order to observe this pulse, it was necessary to devise an assay that allowed us to
measure the internal indole concentration associated with bacterial cells. Previously,
all discussion about the effects of indole involved using the supernatant concentration
of the molecule, but we needed to measure cell associated indole to validate our theory.
Two independent methods were used to probe this [143]. Dr. Hannah Gaimster
(Summers’s laboratory) used a modified Kovacs assay− this is the standard fluorimetric
assay [161] used to determine indole concentrations. However, the Kovacs assay has
limited sensitivity at low indole concentrations, and the modifications required to
study cell associated indole reduced the SNR considerably. We therefore devised a
complementary technique to measure cell associated indole via its UV absorbance
characteristics, and it is this assay and its results that form the basis of this chapter.
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5.2 Measuring Cell Associated Indole
5.2.1 UV Absorbance Assay
Cell associated indole was determined bymeasuring the reduction in supernatant indole
concentration due to the presence of bacterial cells. Briefly, indole is added externally
to a bacterial suspension, and the solution is centrifuged to separate out the cells.
Some of the indole is absorbed by the cells, thus reducing the supernatant indole
concentration. This is at least partly due to the fact that indole is lipophilic, and
preferentially partitions into lipids [143].
The reduction in supernatant indole concentration was quantified bymeasuring the UV
absorbance of the indole in the supernatant and comparing it with a calibration control
in which no bacteria were present. To avoid any contamination from intracellular
indole, a tryptophanase knockout strain of E. coli (W3110 ΔtnaA) was used − since
they lack tryptophanase these bacteria cannot produce indole, and the only indole in
the experiment is that which is added externally. The outline of the assay is shown
schematically in Figure 5.2 and the exact experimental procedure is provided below.
5.2.2 Experimental details
Cells were cultured overnight to stationary phase in a Luria Bertani (LB) medium
(Sigma Aldrich) at 37 oC in shake flasks at 250 rpm. The strain used was Kanamycin
resistant, so 30 μg/ml Kanamycin (Sigma Aldrich) was added to the growth culture to
prevent contamination from other strains. The strain itself was grown on an LB-Agar
plate (Sigma Aldrich) with the appropriate amount of Kanamycin added. Generally,
about 30 ml of each culture was prepared.
The cells were resuspended in Phosphate Buffered Saline (PBS, Sigma Aldrich) for use
in the absorbance measurement. The buffer was autoclaved prior to use and stored at 4
oC. Before each experiment, the buffer was also sterile filtered through 0.22 μm filters
(Millipore).
A 75 mM stock solution of indole was prepared by dissolving indole (>99% pure,
Sigma Aldrich) in absolute ethanol (Sigma Aldrich).
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Figure 5.2 – UV absorbance assay to determine the absorption of indole by cells.
Indole is added externally to a suspension of E. coli bacteria that are incapable of
producing their own indole. Since indole diffuses freely across cell membranes [149]
and is lipophilic [143], a fraction of the externally added indole is absorbed by the cells.
The solution is centrifuged and the indole that was absorbed by the bacterial cells is
thus separated from the supernatant. The bacterial pellet is discarded, and the amount
of indole left in the supernatant quantified by measuring its absorbance in the UV.
Comparing this with a calibration curve enables us to determine the amount of indole
associated with the cell pellet.
The spectrophotometer used was a UV VIS Varian spectrometer (Cary 300 Bio) and
the software package used was the accompanying Cary ‘Scan’ program. The same
quartz cuvette (Sigma Aldrich Z276677-1EA) was used for all experiments. After each
spectrophotometer measurement involving indole, the cuvette was rinsed with 96%
ethanol and dried with nitrogen before the next measurement to remove any trace
indole contamination.
After all mixings/resuspensions, the samples were vortexed to ensure a uniform distri-
bution of bacteria and indole.
The basic protocol was as follows:
1. The bacteria (in LB) were spun down in a Harrier 18/80 Refrigerated Centrifuge
at 4,000 rpm (2,685 × g) for 10 minutes. The supernatant was discarded, and the
bacteria resuspended in a similar amount (∼ 30 ml) of PBS. This was then again
centrifuged at 4,000 rpm for 10 minutes, so that the bacteria were washed with
the buffer.
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2. After the PBS wash, the supernatant was again discarded and the bacteria resus-
pended in a suitable amount of PBS. It is at this stage that one can modify the
bacterial number density in the culture; we chose to concentrate the bacteria by
resuspending them in 7.5 ml of PBS. The higher bacterial density improves the
SNR in the assay.
3. We measured the optical density at 600 nm (OD600) of the bacterial culture in the
PBS. This is a standard method of determining the number density of bacterial
cells in a culture. The higher the number of cells, the higher the optical density.
As with all other measurements in the experiment, this was repeated thrice and
the average value taken. Our final experiments used samples with an OD600 of
between 4.0-5.0.
4. Once the OD600 measurements were complete, we took 1 ml of the bacterial
sample in a microtube (Axygen boil-proof 1.5 ml) and added the appropriate
amount of 75 mM indole stock to it to obtain the desired indole concentration.
For our ‘blank’, we used 1 ml of the bacterial sample without indole. After
spinning these samples down in a centrifuge (Thermo Scientific Heraeus Fresco
17) at 6,000 rpm (3,500× g) for 5 minutes, we saved the supernatants for analysis
and discarded the pellets.
5. Since the indole concentrations we studied were in the range 0.5-2.0 mM (which
saturated the UV VIS reading), we had to dilute all our samples 1:20 by volume
in PBS.
6. Finally, the absorbance curves (in the 250-300 nm range) of the samples were
measured in the spectrophotometer. These absorbance curves were normalised
by subtracting the absorbance curves of the backgrounds − for the bacterial
solutions, we used the bacterial sample without indole (the ‘blank’).
To check that the basic premise of the experiment was correct, we added 1.5 mM indole
externally to two samples of bacteria, one at a lowOD600 (1.8) and one with a very high
OD600 (16.7). Since the sample with the high OD600 contains many more bacterial cells
(for the same volume) than the low OD600 sample, one would expect more indole
to be removed from the supernatant in the high OD600 case. The absorbance curves
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Figure 5.3 – UV absorbance curves for the supernatant when an indole concentration
of 1.5 mM was added externally to control/bacterial solutions. The solutions were
all diluted 20-fold to ensure the absorbance values remained within the linear regime
of the spectrophotometer. A small decrease in absorbance was observed between the
PBS control and the low OD600 bacterial sample (OD600= 1.8). However, the high
OD600(OD600= 16.7) sample absorbed significantly more indole, as evidenced by the
shift in the indole absorbance curve. This suggested that the bacteria were indeed
capable of absorbing indole, and the amount absorbed increased with the number of
cells present.
of the supernatants should reflect this OD600 dependent change in supernatant indole
concentration. This was observed as expected (Figure 5.3).
5.2.3 Calculation of Cell Associated Indole
To calculate the internal cell indole concentrations from the differences in the ab-
sorbance curves, we needed a calibration curve of absorbance versus indole concentra-
tion. We therefore prepared solutions of 0.5 mM to 2.5 mM indole in PBS, performed
the necessary dilutions and measured the absorbance curves. After subtracting the
background, we picked the peak wavelength in the absorbance curves (268 nm) and
plotted a calibration curve of these peak absorbance values against the external indole
concentration.
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For elucidating the cell associated indole, we used the calibration curve to determine
the indole concentration in the supernatant of our bacterial samples (again using the
absorbance values of the samples at 268 nm), and subtracted this value from the external
concentration. Since we always used 1 ml of sample, we could calculate the number of
moles of indole that were transferred to the bacterial pellet. Using the OD600 obtained
(in PBS), one could then calculate the total cell volume in the bacterial pellet [162], and
hence the apparent cell associated indole concentration.
5.2.4 Results
The results of the absorbance assay are depicted in Figure 5.4. At each external concen-
tration, 4 independent bacterial cultures were tested. The mean OD600 of the samples
used was 4.5 ± 0.2 (after concentration in PBS). As expected, we observed a linear
increase in the cell associated indole concentration as the external concentration was
increased. We also calculated that the cell associated concentration was typically 5-fold
higher than the added external concentration.
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Figure 5.4 – Results of the UV absorbance assay. The apparent cell associated indole
concentration rises linearly with externally added indole, as expected. Error bars
represent standard deviations. We see that the cell associated indole is significantly
higher than the supernatant indole concentration, indicating the cellular absorption of
indole.
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We were particularly interested in the 1 mM external indole case, since this is the
value generally found in culture supernatants. Therefore, we tested the effect of 1 mM
external indole without concentrating the samples in PBS (the mean OD600 for these
samples was 1.3 ± 0.1, N = 4, mean ± s.d). As mentioned earlier, the SNR for these
experiments was worse, but the final result, combining both the high and low OD600
calculations, revealed that at 1 mM external concentrations, the apparent cell associated
indole concentration was 7 ± 3 mM (mean ± s.d, N = 8).
It is thus apparent that bacterial cells absorb indole from the supernatant, and that
the cell associated indole concentration can be significantly higher than the external
(supernatant) indole concentration.
5.2.5 Results on cell associated indole using the Kovacs assay
Dr. Gaimster used a complementary approach to measure cell associated indole (Fig-
ure 5.5). In her assay [143], known concentrations of indole were added to ΔtnaA
E. coli cells in stationary phase, similar to the UV assay described previously. How-
ever, after vortexing and centrifuging the solutions, the cell pellet was analysed for
indole, and the supernatant discarded. So whereas the UV assay measures indole
in the cell pellet indirectly, by measuring how much indole the cells removed from
the solution, this approach measures the indole associated with the bacterial cells di-
rectly. The cells are incubated with Kovacs Reagent (made by dissolving 10 g of p-
dimethylaminobenzaldehyde in a mixture of 50 ml HCl and 150 ml amyl alcohol)
for two minutes, which leads to cell lysis. This allows the Kovacs Reagent to react
with the indole present in the pellet, and the level of indole is quantified with an
absorbance measurement at 540 nm (for full experimental details, please refer to [143]).
The calculation of cell associated indole follows the same technique as that used in the
UV assay, and involves the estimation of the cell volume in the pellet from the OD600
[143, 162].
A comparison of the results from the two techniques shows that the cell associated
indole estimated by the Kovacs assay is ∼2× higher than that estimated from the UV
assay. This is likely caused by systematic errors due to the different protocols for the
two assays. In the UV assay, we only take the supernatant, so contamination from the
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Figure 5.5 – The relation between apparent cell associated indole concentrations and
the supernatant indole concentration as determined by the Kovacs assay. As with
the UV assay, known concentrations of indole were added to ΔtnaA E. coli cells in
stationary phase. The mixture was vortexed and centrifuged, but in this assay the
cell pellet was analysed for indole using the Kovacs reagent. Dotted lines show the
cell associated indole concentrations corresponding to external indole concentrations
capable of shutting down cell division [157]. Data points represent mean ± s.d for at
least 3 independent repeats. Data collected by Dr. Gaimster. The image is taken from
[143].
bacterial pellet is unlikely. However, in the Kovacs assay, it is experimentally almost
impossible to remove all the supernatant from the cell pellet before treating it with
Kovacs Reagent. It is therefore likely that some of the indole detected is not associated
with the pellet, which would lead to a slight overestimation of the cell associated indole.
This could account for the differences in values obtained by the two assays. However,
both assays show that the cell associated indole concentration is significantly higher
than the supernatant concentration. This agrees with our understanding of indole as
a lipophilic molecule. The partition coefficient of indole into E. coli total lipid extract
(Avanti Polar Lipids) was measured by Dr. Silvia Hernandez-Ainsa (log(K) = 1.95 ±
0.12 (N = 9) [143]) and confirmed that indole has a high affinity for lipids.
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5.3 Discovery of the Indole Pulse
Work by Dr. Gaimster had shown that there is a rapid increase in indole production as
bacteria transition from exponential to stationary phase. This leads to indole accumula-
tion inside the cells at a rate faster than its diffusion out through the membrane, causing
a pulse in the level of indole associated with the cell, as seen in Figure 5.6. By comparing
the cell associated indole to the supernatant indole concentrations (Figure 5.5), we see
that the indole pulse leads to cell associated indole concentrations that are high enough
to inhibit cell division via the ionophore mechanism mentioned previously [143, 157].
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Figure 5.6 – The Indole Pulse. When E. coli transition from exponential to stationary
growth, the rapid production of indole leads to a transient increase (i.e, a pulse) in
the cell associated indole. The high cell associated indole concentration leads to the
blocking of cell division via the ionophore mechanism described earlier [157]. The
data for this figure was obtained by Dr. Gaimster, and the figure is taken from [143].
Furthermore, we showed that this pulse leads to better long term cell viability − cells
lacking the tryptophanase gene had lower viability than the wild type strain when
monitored over a period of 10 days in low nutrient settings [143]. It was also observed
that simply adding 1 mM indole − the supernatant concentration generally associated
with stationary phase cultures − to these tryptophanase knockouts could not restore
the wild type viability, thus suggesting that the internal indole pulse is crucial for this
long term survival phenotype. We proposed that the pulse signals a decline in available
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nutrients, thus inducing the metabolic changes required to slow down growth in the
hope of conserving the limited resources for long term use [143].
We expect most of the cell associated indole to exist within the lipid membrane. It
is therefore possible that the indole pulse plays a significant role in modulating the
properties of proteins anchored in the E. coli membranes. Since the membrane is the
bacterium’s main protection against external stress, it is likely that indole plays an
important role in the bacterial stress response. We shall briefly discuss the role of indole
in antibiotic resistance below, and shall conclude by returning to our permeability
assay, to examine whether indole affects the lipid permeability of antibiotics.
5.4 Indole and Bacterial Stress Response
5.4.1 Indole response under antibiotic stress
We know that indole is a proton ionophore that is capable of depolarising the E. coli
membrane potential and inhibiting cell division [157]. It should thus come as no
surprise that cell viability is dramatically reduced when the bacteria are incubated with
high concentrations (>4.5 mM) of indole [163]. In fact, ionophores are typically used
as antibiotics due to their toxicity [164]. Thus too much indole is certainly problematic
for a bacterium.
However, indole has also been routinely linked with stress responses in bacteria [144,
153]. While conducting experiments to determine phenotypes in the emergence of an-
tibiotic resistance, it was discovered that when bacteria were grown under norfloxacin
stress (at sub-MIC levels), a few cells became highly resistant, and these isolates started
producing copious amounts of indole [155]. The presence of this indole in the medium
led to an improved antibiotic tolerance for the wider population, but came at a fitness
cost to the producers [155]. This ‘bacterial charity work’ established the existence
of an indole mediated population-based resistance mechanism to norfloxacin [155].
The molecular mechanism of this process is still not well understood, although it
is believed to be linked with the indole mediated overexpression of multidrug eﬄux
pumps [153, 155].
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In order to test this physically, one first needs to know whether the presence of indole
affects the passive permeability of antibiotic molecules across lipid membranes. We
therefore decided to test the effect of a high indole concentration (5 mM) on the
permeability of norfloxacin across DPhPC vesicle membranes to see whether it changed
the drug’s permeation properties.
5.4.2 Lipid permeability of norfloxacin is indole independent
Figure 5.7 – Permeability coefficient histograms showing the permeability of
norfloxacin across DPhPC lipid membranes at pH 7 in the presence and absence
(ethanol control) of indole. Both populations overlap, implying that indole does not
affect the passive diffusion of norfloxacin across lipid membranes.
We performed our optofluidic permeability assay on DPhPC vesicles incubated with
5 mM indole. The indole stock was dissolved in absolute ethanol, so the control
experiments were performed using an equivalent amount of ethanol (without indole)
in the assay solutions. The measurements were performed at pH 7 in the ‘Long’ chip,
and the rest of the protocol was the same as the initial norfloxacin-DPhPC protocol.
The resultant histograms of the permeability coefficients are shown in Figure 5.7.
As is evident, the presence of the indole has no detectable effect on the diffusion of
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norfloxacin across the lipid membrane. It is therefore likely that indole does not in-
fluence passive transport, and that its effects are limited to modulating active transport
processes [153]. The study of the effect of indole on these transmembrane transport
proteins is an important avenue of research, but lies beyond the scope of this Thesis.
5.5 Conclusions
We have provided a small glimpse into the ever expanding field of indole signalling in
bacteria. The pulse signalling mechanism is a new entrant to this field, and much work
is still required to pin down its mechanisms and downstream effects. There are many
examples of indole playing important signalling roles, but the molecular mechanisms
involved have so far proved elusive.
Apart from the microbiology and antibiotic resistance perspective, the presence of
indole and indole producers in the human gut is of great interest, especially in light
of the recent results highlighting the effect of indole on the human glucose metabolism
[148]. Understanding bacterial signalling processes in the gut is thus crucial for de-
veloping a broader understanding of host-microbiome interactions. And this is just
one example − the number of bacteria colonizing the human body outnumber all
the ‘human’ cells in our bodies 10 to 1. Metabolites produced by gut bacteria have
been shown to affect plasma concentrations of various mammalian blood metabolites
[165, 166]. Furthermore, the lining of the digestive tract is home to the enteric nervous
system which consists of approximately 108 neurons of various different types [167,
168]. Investigations are already underway linking changes in the gut microbiome
with changes in behaviour, and this promises to be an extremely interesting field of
biomedical research in the near future [169]. Along these lines, it is worth considering
the fact that the indole ring is found in various chemicals known to affect the nervous
system, from the ‘sleep chemical’ serotonin to hallucinogens such as psilocybin. 90% of
the serotonin in our body is produced in the gut, and experiments have already shown
that both human and mouse gut microbes regulate their host’s serotonin biosynthesis
[170]. One could easily speculate on the role of indole, produced by gut bacteria, in
controlling the human nervous system via similar pathways.
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Which begs the question, who really is in charge, humans or bacteria? Only time will
tell.
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Chapter 6
Outlook
“We are made wise not by the recollection of our past, but by the responsi-
bility for our future.”
George Bernard Shaw
6.1 Vesicle based permeability measurements
Vesicles offer, in principle, an excellent platform for studying transport across lipid
bilayers, as evidenced by the work described in this Thesis and elsewhere [13, 19, 56].
However, a lack of precise control over vesicle formation using traditional electrofor-
mation or lipid hydration techniques has placed limitations on the field. As a result,
most membrane protein research today is carried out using planar lipid membranes,
which lack the curvature and spherical continuity of true cellular membranes [171], in
addition to being incompatible with conventional microscopy techniques.
The use of microfluidics for vesicle formation has provided a much needed impetus
to the field. These techniques generally involve focussing an aqueous solution in a
cross flow of a lipid/oil solution. The resultant lipid-stabilized droplets are converted
into vesicles by merging the droplet flow with another aqueous solution, which is
accompanied with the removal of the oil phase [43, 141, 142, 171]. The use of mi-
crofluidic flow patterns enables precise control over vesicle formation − the vesicles
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AqEX Oillipid AqIN
Step
Figure 6.1 – Microfluidic vesicle formation. A) The internal aqueous dispersed phase
(AqIN) is sheared by a carrier oil flow producing monodisperse water-in-oil emulsion
droplets (scale = 70 μm). B) Image of channel meander, where the spontaneous
formation of a lipid monolayer around each aqueous droplet can take place (scale =
80 μm). C) Step junction (scale = 100 μm), where the channel carrying the water-in-oil
droplet changes depth from 50 μm to 100 μm. This allows the emulsions to transfer
into the external aqueous phase (AqEX). The red line indicates where the PDMS has
been treated in the deeper channel to prevent the wetting of each droplet on the channel
wall. Image and description taken from [141].
produced are of uniform size, the diameter can be tuned and solutes can be efficiently
encapsulated [171]. Preliminary studies have shown that protein pores can be inserted
in these vesicles leading to the permeabilization of the membrane [171]. Although the
experimental techniques involved are far more challenging than conventional electro-
formation, the significant improvement in vesicle formation control offered must mean
that these microfluidic techniques will soon become the norm.
This bodes well for our permeability assay. A microfluidic chip redesign would allow us
to incorporate the vesicle formation on chip, significantly improving throughput and,
additionally, simplifying the analysis. Lipid aggregates would not be a problem, and the
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uniformity in vesicle size would make it easier to filter out false events. It should also
then be possible to mix nanopores with the vesicles on chip, which should make the
pore insertion efficiency more uniform across the vesicles. In principle, fluorescently
tagged pores could be used to quantify the number of pores attached to the vesicle
membrane, enabling a more precise measurement on the flux of the solute of interest
through the pore. Thus incorporating microfluidic vesicle formation into our assay
would be the obvious next step in developing the technology.
6.1.1 Antibiotic transport studies
First and foremost, our assay could be used to characterize the permeability of vari-
ous antibiotics across a range of different lipids. Lipid mixtures containing the lipid
molecules found in bacterial membranes could be used to create vesicles that more
closely mimic true bacterial membranes. As demonstrated with norfloxacin, the pH
dependence of antibiotic transport can be investigated for a host of different drug
molecules. Furthermore, the effects of ions such as Mg2+ on antibiotic transport could
be investigated. Metal ions can chelate antibiotics and this can change the solubility,
pharmacokinetics and bioavailability of these drugs [172].
Secondly, the role of different membrane protein pores on antibiotic transport can
be quantified using our technique. However, for this we shall first have to develop
better control over quantifying the porin insertion efficiency, for which the microflu-
idic developments of vesicle formation and pore incubation are crucial. Nevertheless,
there are many different membrane protein pores that are yet to be analysed by this
technique, and the selectivity of pores for particular antibiotics could be investigated.
The technique need not be limited to passive diffusion. Vesicles have been used to study
active transport using eﬄux pumps reconstituted in lipid vesicles [173]. Such transport
processes could also be investigated using our technique, although one must bear in
mind that the theoretical model will have to be modified appropriately to study active
rather than passive transport.
Finally, one need not limit oneself to the study of protein pores. Our research group
has recently succeeded in creating nanopores made out of DNA origami [174]. Further
work has shown that these can be reconstituted into lipid bilayers, raising the possibility
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that these structures could one day be used as artificial membrane channels enabling
the transport of ions or drugs into target cells [175, 176]. We are in the process of
optimising the insertion of these pores into vesicles to test their ability to transport
drugs across the lipid bilayer.
6.1.2 Ion flux measurements
The assay we have developed is a very general technique. The experiment only requires
that the entity under investigation show fluorescence. Thus we are not just restricted to
antibiotics, we can study the transport of any drug or solute molecule that is fluorescent
and quantify its lipid permeability.
One field that is extremely important in biology is the field of ion transport. The
proper balance of ions between the interior and the exterior of a cell is critical for
its survival. Besides maintaining the correct osmolarity and membrane potential, ions
are involved in various cell signalling processes. For example, Ca2+ signalling is used
to control processes ranging from fertilization, proliferation, development, learning
and memory, contraction and secretion, and all this must be tightly regulated since
deviations in the spatial or temporal boundaries of Ca2+ signalling can cause cell death
[147, 177, 178]. Ca2+ can be derived either from internal stores within the cell, or from
the external surroundings via channels in the membrane [146]. Defects in calcium
channels have been linked with a number of serious neurological, cardiac, retinal and
muscular disorders in humans [179].
Given the obvious importance of studying calcium signalling and transport, a number
of highly sensitive dyes have been developed that are capable of detecting physiological
concentrations of Ca2+ in cells [180]. One such dye, developed in the group of the
Green Fluorescent Protein pioneer Roger Tsien, is Fura-2 [181]. The fluorescence
characteristics of the dye are shown in Figure 6.2. Fura-2 is a divalent metal ion chelator
that changes its fluorescence properties on complexation [182]. In the absence of Ca2+,
the unbound form of Fura-2 has a peak excitation wavelength around the 370 nm
mark, which shifts down to around 340 nm when the Ca2+ is bound. By switching
between 340 nm and 370 nm excitation wavelengths, one can obtain intracellular Ca2+
concentrations using a ratiometric approach [180].
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Figure 6.2 – Fura-2 pentasodium salt (Life Technologies) fluorescence characteristics.
Emission wavelength λem = 510 nm. When Ca2+ ions are bound to the dye, the
excitation maximum is at around 340 nm, whereas the unbound form of the dye has
an excitation maximum around 370 nm. We can exploit this to study Ca2+ transport
into nanopore embedded vesicles in the same way as we studied norfloxacin transport.
Using 340 nm as our single beam excitation wavelength, we can track Ca2+ ions as
they accumulate in vesicles by studying the increase in fluorescence intensity within
the vesicles. The Fura-2 fluorescence characteristics were measured by T. Maier on a
Cary Eclipse fluorimeter. Solutions contained 5 μM Fura-2, 140 μM EGTA as chelator
for divalent impurities and 200 mM sucrose.
However, from Figure 6.2, it is clear that we can study Ca2+ transport across proteoli-
posome membranes using this dye without requiring a ratiometric measurement. By
stimulating the dye’s fluorescence at 340 nm, one can distinguish solutions flowing in
the chip in which Ca2+ ions are present (bound to Fura-2) or absent. One can prepare
vesicles containing Fura-2 and a chelator (Ethylene Glycol Tetraacetic Acid, EGTA, to
remove any trace divalent impurities in the buffer) − this forms the solution in one
inlet of the T junction, whereas the other inlet contains the same buffer with Ca2+
ions. The transport of the Ca2+ ions into the vesicles can be tracked by studying the
increase in autofluorescence intensity (at an excitation wavelength of 340 nm) within
the vesicles.
Of course, being charged the ions cannot simply diffuse across the lipid bilayer. We
have incorporated alpha-hemolysin, a bacterial toxin nanopore, into the vesicles and
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are in the process of studying Ca2+ transport through these pores. With the hemolysin
measurement as a positive control, we can investigate the ion transport properties of
new DNA origami nanopore structures by embedding these in the vesicle membranes.
Besides Ca2+, there are dyes available to track Na+ and K+ ions as well, and thus our
system can be used to investigate the ion transport characteristics of a range of different
nanopores, thus opening up yet another field of investigation with this technique.
6.2 Transport measurements on the single cell level
The main advantage of using vesicle based model systems is that one has complete
control over the transport process. One knows that all transport must be passive
(unless designed otherwise), and once the baseline membrane permeability has been
determined, it is possible to study the effect of additional membrane components on
drug (or ion) transport.
However, in many cases one just wants to know whether a drug or nanoparticle enters
a cell, and how long such a process takes. For example, if one has a sample of bacteria
from a clinic, by performing a drug transport assay one could screen the population for
antibiotic resistant cells based on their reduced drug uptake (Figure 6.3). In principle,
our microfluidic chip could be redesigned into an autofluorescence based cell sorter
which could separate bacteria based on their relative rates of drug uptake (for a review
of label-free microfluidic cell sorting, the reader is referred to [183, 184]). These cells
could then be analysed using genomic and proteomic techniques to study the precise
mutations that led to reduced drug uptake.
Performing such studies on lab-on-chip devices would enable clinicians to spot mu-
tations quickly and, in an ideal scenario, change the therapy such that the resistance
pathway could be overcome. This could be useful not just for bacterial infections but
also for cancer diagnosis and treatment, another setting in which drug resistance plays
an important role.
A number of eukaryotic cell types can be analysed in the microfluidic devices we
already possess. For example, we have tested HL60 cells (a leukemia cell line) in our
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Figure 6.3 – Schematic of a proposed microfluidic system that sorts bacterial cells on
the basis of antibiotic uptake. The levels of drug autofluorescence within the cell after
exposure to the drug in a T junction chip determine whether the uptake is normal or
reduced. Reduced uptake is often a sign of antibiotic resistance [23], and such cells
would be separated using a cross flow. The cells could then be subjected to detailed
biochemical analyses to determine the cause of resistance.
devices, and showed that similar transport measurements could be performed using
these cells.
With bacteria, their small size becomes a challenge. We have constructed channels that
are 10 μm wide and 6 μm high, in which we were able to see E. coli flowing through
the channels. However, flow control for the long network lengths is challenging with
such narrow channels, and the small size of the bacteria also makes imaging them
difficult. The use of faster cameras and high magnification objectives should, however,
make this system viable in the future. Another option, especially when considering
making a portable device, would be using photomultiplier tubes as the detectors and
designing a confocal detection system. The fluorescence intensity at particular points in
the network could be monitored − the drug accumulation in an individual bacterium
would be a function of the fluorescence intensity dip recorded by the detector as
the bacterium passes through the detection volume. PMTs are also much faster than
standard cameras, which would increase the throughput, and reduce the time taken
to sample a bacterial population. Another corollary to this would be that one could
obtain an accurate estimate of the bacterial concentration at the same time, which
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would provide an added bonus when characterising bacterial infections in the clinic.
There is thus significant incentive to develop such technology.
6.3 Future measurements on indole signalling
With the indole project, there are many possible avenues to pursue. The first thing that
will need to be investigated in detail is the actual mechanism of indole production. We
know that indole is produced when bacteria face external stresses, but the molecular
mechanisms and pathways involved in the response are unclear.
One would also like to quantify indole production on the single cell level. We have
two possibilities in this regard − indole production can be detected indirectly inside
cells by using the pSTYABB plasmid, which encodes styrene mono-oxygenase. This
enzyme converts indole molecules into indigo, a dye whose levels can be quantified by
colorimetric assays [149, 160].
The timing of indole production can also be inferred by studying the expression of
tryptophanase. This can be done using a bacterial strain in which green fluorescent
protein (GFP) is tagged to tryptophanase expression. With this in hand, it should
be possible to perform a number of experiments in which single bacterial cells are
exposed to a range of stresses, and tryptophanase expression monitored using the GFP
fluorescence to study the role of indole in the stress response.
Single cell studies, however, cannot be performed efficiently using standard microbiol-
ogy protocols. Here again, microfluidics can come to the rescue. High throughput,
single cell studies of bacterial growth have become technologically feasible with the
invention of the “Mother Machine”, a microfluidic chip used to study various aspects
of bacterial growth [185]. A similar device could allow us to control the microenviron-
ment in ways conducive to studying stress responses in growing bacteria.
Another interesting possibility is that the indole pulse might be a stochastic process
occurring continuously in bacterial colonies, that preconditions certain individuals
in a bacterial colony to be able to withstand any type of stress. This would have
implications for the study of bacterial persistence, which is almost as great a medical
problem as antibiotic resistance [186–188]. Persisters are the cells in the colony that
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become dormant due to natural stresses, and their metabolic inactivity allows them to
escape the effects of antibiotics. These cells can survive antibiotics without having
undergone the mutations typically seen in resistant organisms. Once the stress is
removed, these cells start growing again, leading to a recurrence of the infection. Their
transient nature and relatively low numbers in colonies has impeded the study of
persisters, and the molecular mechanisms behind their phenotype are largely unknown
[188]. The indole pulse could potentially be one such mechanism regulating persistence
in bacteria. Again, microfluidic investigations on single cells would offer a platform into
the analysis of this phenotype, and an ability to separate these cells will hopefully open
the field up to detailed biochemical investigation.
The role of indole signalling in the human gut is already under investigation [145, 148].
However, all the studies performed so far have been based on cells grown in cultures.
The next step here would be to study the effect of indole positive and indole negative
bacteria directly in the gut. This is typically done using ‘germ-free’ mice, which are
grown in special aseptic conditions so that they are born free of any microbes. Growing
these mice is experimentally challenging, but they are ideal systems for experiments
studying the effect of particular gut bacteria on physiology [189]. Germ-free mice
colonized by indole producers could be studied and compared with those colonized by
indole non-producers, and effects on metabolism, blood metabolites and other physio-
logical parameters monitored.
It is thus apparent that the indole project spans many different fields of study, and it
would be presumptuous in the extreme to suppose that any one individual or research
group could pursue all the leads. However, the rewards for studying these various
aspects of indole signalling could be substantial, and one hopes that the elucidation of
the pulse mechanism is just the beginning of a long road of discovery in the field.
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Chapter 7
Concluding Remarks
“I did, what I had to do. And saw it through, without exemption.”
Frank Sinatra (My Way)
This Thesis has been devoted primarily to the development of a new technique capable
of quantitatively studying the passive diffusion of drugs through model lipid mem-
branes. We applied this optofluidic assay to the investigation of the lipid permeability of
the antibiotic norfloxacin, and validated theoretical predictions of the pH dependence
of norfloxacin permeability. We also demonstrated the importance of lipid composi-
tion on drug permeability by measuring norfloxacin permeability across lipid bilayers
constructed from different lipid molecules.
By reconstituting OmpF pores in our vesicle membranes, we were able to develop a
new technique for investigating antibiotic transport through these membrane protein
nanopores. Our reductionist approach allowed us to quantify drug transport through
the lipid membranes and pores separately, and enabled us to propose a physical mecha-
nism that explains the pH dependence of antibiotic susceptibility in E. coli.
We also used our technique to measure the lipid permeability of the antibiotic tetra-
cycline. Our measurements agreed well with theoretical predictions of tetracycline
permeability that were based on considerations of the multiple possible protonation
states of the molecule. Our technological developments have laid the foundations for
a detailed investigation into the environmental factors that affect the lipid permeability
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of different drug molecules, which we believe will be of great use in optimizing drug
delivery and efficiency.
Finally, we presented results on a novel signalling mechanism that we discovered in
E. coli. In our present battle against antibacterial resistance, the importance of under-
standing bacterial communication and stress responses cannot be overstated. We believe
that the indole pulse signal could be a vital component of the bacterial arsenal against
external stress, and future investigations have been planned in an attempt to unlock the
indole pulse on a molecular level.
As discussed in the Outlook chapter 6, we have many different avenues to investigate,
both from the perspectives of technology development and fundamental molecular
biology. With the battle against drug resistant pathogens looming large, one must
leave no stone unturned in the quest for a solution that would prevent a return to the
dark ages of pre-antibiotic medicine.
However, the beauty of biology is that there are many unknowns, and one hopes that
with new discoveries, no medical problem will prove insurmountable. In spite of all the
scientific advancement over the past century, we are still a long way from a complete
understanding of how even a single living cell functions. The work presented in this
Thesis is but an incremental advance in this direction. Shakespeare’s words still ring
true today − there are, indeed, far more things in this World, than are dreamt of in our
philosophy. With perseverance, however, we might still find some of them.
Appendix A
Protocol for the Optofluidic
Permeability Assay
1. Prepare DPhPC (or other lipid) vesicles (in 200 mM sucrose, in 5 mM phosphate
buffer made by mixing 5 mM solutions of KH2PO4 and K2HPO4 in deionized
(Millipore) water in a beaker till the pH reaches 7). For pH 5, use 5 mM acetic
acid as the buffer.
2. Prepare the PDMS chip by pouring approximately 36 g of the PDMS mixture
(9:1 elastomer:curing agent ratio) onto the Si mold placed in a round plastic petri
dish (for smaller molds, use a flat square weighing boat, and add approximately
21 g of the PDMS mixture). Make sure the petri dish/weighing boat is lined with
Aluminum foil beforehand to ease removal of the mold and PDMS after baking.
The PDMS should be baked for 55 minutes in the oven at 60 oC. Removal of
PDMS from the Si mold must be done carefully using a scalpel, cutting away any
PDMS from the base of the mold using a shallow cutting angle. Avoid putting
pressure on the mold at a steep angle with the scalpel as this can fracture the
mold.
3. The PDMS chip should be cut out as a neat cuboid using a sharp blade; it is easiest
to cut this while keeping the PDMS flat on a thick glass slide on a table top.
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4. Inlet/outlet columns should be punched using a 1.5 mm biopsy punch (Miltex).
Use some spare (flat), set PDMS as the base on top of which you hold the PDMS
chip in which the columns are being punched. Punch through the entire thickness
of the chip and use the plunger on the punch to remove any loose PDMS pieces
from the column.
5. Plasma bind the PDMS chip to the coverslips used (for the water immersion
objective, it is helpful to use 50 x 40 mm Type I coverslips, Assistent, Germany;
the broader coverslips help prevent the movement and evaporation of water). For
this process:
• First clean the PDMS chip with 96% ethanol and blow dry with nitrogen gas.
• Use ‘magic’ scotch tape to clean both sides of the chip thoroughly, especially the
surface that is to be bonded. Simply deposit the tape on the side being cleaned,
and peel off to remove dirt/dust. Repeat 6-8 times on the side being bonded.
• Use the tape to clean the coverslip in a similar manner.
• Place the PDMS chip and coverslip in a plasma cleaner (surfaces to be bonded
facing up) and press PUMP, adjust power to full (setting 10 W), timer to 10 s and
then wait 5 minutes.
• Press GAS, adjust to 25 sccm level and wait 5 minutes.
• Press GENERATE. The count down will begin and stop after 10 s.
• Immediately press (in order) GAS, VENTILATE and (after 5-10 s) PUMP. As
soon as the door is released, press the two surfaces to each other and move over
the edges of the chip (from the glass side) with flat tweezers to ensure bonding.
This must be done within 60 seconds of the plasma being generated.
• Place the bonded chip in the oven at 60 oC for 5-10 minutes to enhance adhesion.
6. Separately, filter (0.22 μmMillipore filters) the buffer to be used in the experiment
(approximately 1 ml) into an Eppendorf tube.
119
7. Prepare 2 mM norfloxacin in the filtered buffer. The norfloxacin stock (around
50 mM) is prepared in deionized water by reducing the pH to about 3 (using
10% HCl) and then slowly increasing it to a pH of 5 by adding 10% KOH. The
norfloxacin only dissolves in water at an acidic pH and is not stable at these stock
concentrations above a pH of 5.
8. Switch on the neMESYS syringe pump system. Switch on the software and fill
the syringe with Millipore water through the tube that will be connected to the
chip outlet. Use a flow rate increment of 100 μl/hr and a suitably high flow rate
( ∼ 8,000 μl/hr) for this step.
9. Through the other tube (yellow on the graphical user interface), pour out the
water till the syringe level is about 80 μl. Stop the flow.
10. Switch back to the flow channel that will be used in the experiment (blue channel
in the software) and ensure the flow rate increment is set to 1 μl/hr.
11. TROUBLESHOOTING: Ensure that there are no air bubbles anywhere in the
tubing/syringe. If there are bubbles, repeat the above steps till they are com-
pletely removed. If simply repeating the above process is not enough to get
rid of the bubbles, unscrew the syringe from the pump and tap the syringe
so that the bubbles move to the mouth of the syringe. Use the software to
switch the flow to the other channel (yellow) and manually push out the liquid
completely. Perform a “Reference Move” using the software (IMPORTANT:
THE SYRINGE SHOULD BE REMOVED FROM THE HOLDER WHILE
PERFORMING A REFERENCE MOVE); this will move the syringe holder
back to the zero position. Reattach the syringe, switch back to the channel used
in the experiment, and repeat steps 8-10 above. You should have now removed
all the air bubbles.
12. Switch on the Monoscan 2000 (Monochromator), open the software and set the
wavelength to 340 nm (norfloxacin excitation wavelength used).
13. Once the chip is bonded, use a 1 ml syringe and type 11 hypodermic needle to
fill the chip with the filtered buffer. Ensure no air bubbles form in the chip.
Since you are filling the chip from all three columns, there will be air trapped in
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the channels. Wait till this disappears before starting the experiment (PDMS is
permeable to air). If there are air bubbles in the columns, it is possible to remove
them by carefully pulling them out with the syringe needle. Take appropriate
(sharps) precautions while working with the needles and dispose of them in the
Sharps Hazards bin.
14. Cut a pipette tip (200 μl, Axygen) near the taper at the tip to obtain a slightly
wider bore. Take up 40 μl of the 2 mM norfloxacin solution into this pipette tip
and stick the pipette tip into one of the inlets (it should be pressed approximately
halfway down the column). Repeat the same procedure for the vesicles solution
in the other inlet (the volume does not have to be 40 μl, it depends on how long
you wish to run the experiment). Blot away any external liquid at the inlets using
dust-free tissue paper (Kimtech).
15. Turn on the camera and the software (μManager 1.4). Set the exposure to 2 ms,
bin 2, clearing pre-sequence (if using the Evolve) or exposure 10 ms, bin 4, clear-
ing pre-sequence if using the optiMOS. Remove the lens cap.
16. Put a droplet of Millipore water on the objective (if water immersion) and place
the coverslip/microfluidic device on it such that the T junction is in the field of
view. For the moment, use the simple LED light source for viewing and aligning
the position of the chip.
17. Find the T junction by moving the stage or moving the chip by hand. Once
found, ensure that the channel lines are straight (if not, rotate the chip by hand
till they are straight). Then fix the coverslip in position using tape.
18. Use the syringe pump to push the liquid out of the tubing (Upchurch 1520G) so
that a droplet forms on the end of the tubing. Once this happens, stop the flow
and insert the tubing into the outlet column in the chip.
19. Set the pump to a flow rate of −30 μl/hr flow to pull the solutions into the
microfluidic network.
20. Turn on the EQ99FC light source by switching on the main power supply,
toggling the ENABLE switch, waiting 5 seconds, then toggling the OPERATE
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switch. Remember, for these switches, UP is ON, and DOWN is OFF. You
MUST wear goggles, and keep the shielding in place when the UV light is on.
On the Olympus IX73 Setup, you simply have to switch on the Prior Lumen
lamp (remember, once this has been turned on it must run for at least 30-45
minutes, and after switching it off let it cool for 1 hour before using it again.
These precautions are not required on the EQ99FC light source, though one
should ideally avoid switching this source on and off repeatedly as well).
21. Once the EQ99FC light source is active (takes about 90-120 seconds after switch-
ing on), focus the image at the T junction. Switch off the LED light source and
set the EM gain to 100 (Evolve).
22. Wait till the two flows are clearly seen (i.e, the autofluorescence of the norfloxacin
will cause the flow arriving from the norfloxacin inlet to be bright whereas the
vesicle flow will be dark).
23. Once the fluorescence intensity stops increasing, reduce the flow speed to about
−3 μl/hr.
24. Wait till the flows settle to the lower value and vesicles start appearing.
25. Once a steady, suitably slow flow rate has been reached, move the chip into the
desired viewing position.
26. Change the settings in the MultiD Acquisition tab in μManager to 5000 frames
with 0 ms intervals (fastest acquisition) and run a preliminary video acquisition.
Remember to save the images as a single stack file and choose an appropriate
name and folder to save the stacks to. Since the amount of data generated is large,
it is advisable to save the files directly to an external hard-drive. Check this video
to ensure that the focal plane is appropriate for the vesicles being detected, and
that each vesicle is being detected for 6-10 frames at least. Adjust the focus/flow
rate accordingly.
27. Once set, go to Tools → Script Panel and run the Repeat Acquisition beanshell
script as required. This basically runs the MultiD acquisition script with its
current settings repeatedly for a specified amount of time.
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28. IMPORTANT: If the images start going out of focus, you should immediately
stop the acquisition and delete any videos it might have affected. You may need
to adjust the focus quite often till it settles. If the water has dried completely,
you will need to put another droplet of water on the objective. This is done by
first switching off the light source via the OPERATE switch, removing the tape
holding the device in place and raising the coverslip gently. This allows access by
the dropper for the water on the objective. Place the coverslip back in position,
make sure the viewing point is the same, tape it down, switch on OPERATE and
continue the acquisition. Repeat till you have about 40-50 good movies (5,000
frames each) at one position. Ideally, do 2-3 viewing points in one experiment.
29. On occasion, there might be some imbalance in the flow due to a slight asymme-
try in the optical table or the inlet fluidic resistance. It is important to balance the
flows to ensure a 1:1 mixing of the two solutions. You may add/remove a small
amount of solution from one of the inlets to balance this. If you suspect one
of the flows has been blocked (this occasionally happens in the vesicle flow due
to a build up of lipid aggregates at the vesicle inlet reservoir), increase the flow
rate substantially (∼ 150-200 μl/hr) till the blockage is removed (you should see
it flow through your field of view). Reduce the flow rate and restart acquisition
once the desired flow rate is achieved. It is also advisable to check that the lipid
aggregate has completely cleared the channel and reached the outlet reservoir
before restarting acquisition.
30. After acquiring your data, it is always a good idea to scan through the part of the
chip you have been studying to ensure that there has been no build up of lipid
deposits that could have affected the flows. You may do this at regular intervals
during the experiment. Lipid deposits can block the flows and distort the mea-
surements of time taken for the vesicles to travel between detection positions, so
this is an important factor to check.
31. Once complete, switch off the light source first (turn off OPERATE, ENABLE
and finally the main power switch for the EQ99FC; for the Prior lamp simply
turn off the main switch). Switch off the camera (software first, then hardware;
remember to cover the camera with the lens cap). Stop the flows completely and
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disconnect the syringe pump from the chip by removing the tubing. Pour out
the liquid from the syringe into a waste container and then switch off the syringe
pump (software first, then mains). Switch off the monochromator software and
then hardware. Ensure the LED light source is also off.
32. Remove the chip from the setup and dispose of it in the Sharps bin. Blot away
any remaining water from the objective using lens cleaning tissues (Thorlabs).
33. Cover the objective with a lens tissue, and close down the setup.
34. All liquids should be disposed off in the Aqueous/Unchlorinated Waste bottles
as appropriate.
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Appendix B
Microfluidic Chip Designs
The outlines of the 3 microfluidic chip designs used are presented. In all three designs,
the inlet reservoirs show the two sets of filter pillars used, the first being a coarse filter
(75 μm gaps) and the second a fine filter (40 μm gaps). These were included to prevent
large lipid aggregates from entering the channels and blocking the flows.
Photolithography of the ‘Short’ design Si mold
A silicon substrate was covered with a thin layer of adhesion promoter (Omnicoat,
Microchem, spin coating: 2,000 rpm for 30 seconds) following which a layer of SU-8
2025 (Microchem) was deposited (2,000 rpm, 30 seconds). This was pre-baked (2 mins
at 65 oC, 5 mins at 95 oC) and selectively exposed to UV (12 seconds, 365-405 nm, 20
mWcm-2) through a bespoke pellicle mask created using the AutoCAD design (Photo-
data Ltd.). The sample was then post-baked (1 min at 65 oC, 3 mins at 95 oC), developed
for 3 mins, dried with N2 and hard baked for 5 mins at 95 oC. This protocol yields
channels with a height of 43 μm. The shallower channel is advantageous, since it keeps
the vesicles in better focus during imaging.
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Figure B.1 – ‘Long’ chip design. The length from the T junction to the outlet reservoir
is about 380 mm. Channels are 40 μm wide and 50 μm high. This design is used for
experiments where significant drug diffusion across the vesicle membrane occurs on a
timescale of minutes. The design contains 15 different viewpoints. This design was
used for the norfloxacin-DPhPC results presented in chapter 3.
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Figure B.2 – ‘Medium’ chip design. The length from the T junction to the outlet
reservoir is about 127 mm. Channels are 40 μm wide and 50 μm high. This design
is used for experiments where significant drug diffusion across the vesicle membrane
occurs on a timescale of minutes. The design contains 4 different viewpoints. This
design was used for the Quantum Dot measurements presented in chapter 3.
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Figure B.3 – ‘Short’ chip design. The length from the T junction to the outlet reservoir
is about 28 mm. Furthermore, the initial (t = 0) viewpoint can be much closer to the
T junction than in the other designs; the detection point typically used was reached by
vesicles within a second after passing the T junction. The channel width is 40 μm and
the height is 43 μm. This design was used for all the fast permeation experiments
described in this Thesis − the norfloxacin-DOPC, tetracycline-DPhPC (chapter 3)
and OmpF measurements (chapter 4). It is also the design being used to study Ca2+
transport through hemolysin nanopores (chapter 6).
Appendix C
Theoretical basis for the linear
relationship of ΔI(0) vs R
The autofluorescence intensity (I ) of drug molecules is proportional to the number of
molecules (N ) being imaged:
I = αN = αcV (C.1)
where c is the concentration of the drug molecules in the imaging volume V.
However, in our image analysis, we always calculate the intensities in a 5×5 pixel area
around the centre of the vesicle. Therefore, we can simplify the above equation to:
I = βcl (C.2)
where β is the modified proportionality constant which includes the constant area term,
and l now refers to the height of the imaging volume.
Now, we have:
ΔI =
Iout − Iin
Iout
(C.3)
Using our analysis from above:
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Iout,coutIin,cin
r
h 2r
Figure C.1 – Schematic depicting a vesicle of radius r in a microfluidic channel of
height h. Drug fluorescence intensity outside the vesicle Iout corresponds to a drug
concentration cout. However, the fluorescence Iin measured at the centre of the vesicle
contains fluorescence contributions due to both the drug inside the vesicle (cin) as well
as background fluorescence due to the drug molecules that are present in the space
between the vesicle and the channel walls.
Iout = βhcout (C.4)
and
Iin = β(h− 2r)cout + β2rcin (C.5)
where h is the height of the microfluidic channel and r is the vesicle radius (Figure C.1).
Using the above equations, ΔI reduces to:
ΔI =
2r
h
×
(
cout − cin
cout
)
(C.6)
But at t = 0, cin(0) = 0. Therefore, we find:
ΔI(0) =
2r
h
(C.7)
We thus obtain a linear relation between ΔI(0) and vesicle radius r in our calibration
curves (for example, see Figure 2.13). In practice, there are other optical effects which
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prevent us from realising a ΔI(0) value of 1 when 2r = h. However, this analysis offers
a simple explanation for the linear trends we observe in our experiment.
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